Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2017 | Aug. 11, 2017 | |
Document Information [Line Items] | ||
Entity Registrant Name | AMYRIS, INC. | |
Entity Central Index Key | 1,365,916 | |
Trading Symbol | amrs | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 37,606,558 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Assets | ||
Cash and cash equivalents | $ 5,078 | $ 27,150 |
Restricted cash | 3,815 | 4,326 |
Short-term investments | 1,556 | 1,374 |
Accounts receivable, net of allowance of $501 and $478, respectively | 15,958 | 13,105 |
Related party accounts receivable, net of allowance of $23 and $23, respectively | 1,431 | 872 |
Inventories | 5,729 | 6,213 |
Prepaid expenses and other current assets | 7,440 | 6,083 |
Total current assets | 41,007 | 59,123 |
Property, plant and equipment, net | 49,303 | 53,735 |
Restricted cash, non-current | 958 | 957 |
Equity and loans in affiliates | 94 | 34 |
Other assets | 20,783 | 15,464 |
Goodwill and intangible assets | 560 | 560 |
Total assets | 112,705 | 129,873 |
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Accounts payable | 14,657 | 15,315 |
Deferred revenue | 5,001 | 5,288 |
Accrued and other current liabilities | 29,275 | 29,188 |
Capital lease obligation, current portion | 598 | 922 |
Debt, current portion | 7,954 | 25,853 |
Related party debt, current portion | 5,331 | 33,302 |
Total current liabilities | 62,816 | 109,868 |
Capital lease obligation, net of current portion | 33 | 334 |
Long-term debt, net of current portion | 111,112 | 128,744 |
Related party debt, net of current portion | 40,920 | 39,144 |
Deferred rent, net of current portion | 8,445 | 8,906 |
Deferred revenue, net of current portion | 6,650 | 6,650 |
Derivative liabilities | 58,606 | 6,894 |
Other liabilities | 5,639 | 7,841 |
Total liabilities | 294,221 | 308,381 |
Commitments and contingencies (Note 6) | ||
Stockholders’ deficit: | ||
Preferred Stock - $0.0001 par value, 5,000,000 and 5,000,000 shares authorized as of June 30, 2017 and December 31, 2016, respectively, and 3,330 and 0 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively | ||
Common stock - $0.0001 par value, 250,000,000 and 500,000,000 shares authorized as of June 30, 2017 and December 31, 2016, respectively; 25,272,420 and 18,273,921 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively | 3 | 2 |
Additional paid-in capital - common stock and other | 1,012,906 | 990,895 |
Accumulated other comprehensive loss | (42,003) | (40,904) |
Accumulated deficit | (1,171,189) | (1,134,438) |
Total Amyris, Inc. stockholders’ deficit | (200,283) | (184,445) |
Noncontrolling interest | 937 | 937 |
Total stockholders' deficit | (199,346) | (183,508) |
Total liabilities, mezzanine equity and stockholders' deficit | 112,705 | 129,873 |
Contingently Redeemable Common Stock [Member] | ||
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Mezzanine Equity | 5,000 | 5,000 |
Convertible Preferred Stock [Member] | ||
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Mezzanine Equity | $ 12,830 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Allowance for doubtful accounts | $ 501 | $ 478 |
Related party accounts receivable allowace | $ 23 | $ 23 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 3,330 | 0 |
Preferred stock, shares outstanding (in shares) | 3,330 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 250,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 25,272,420 | 18,273,921 |
Common stock, shares outstanding (in shares) | 25,272,420 | 18,273,921 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Renewable product sales | $ 12,729,000 | $ 4,922,000 | $ 21,021,000 | $ 8,062,000 |
Grants and collaborations revenue | 12,950,000 | 4,677,000 | 17,639,000 | 10,347,000 |
Total revenues | 25,679,000 | 9,599,000 | 38,660,000 | 18,409,000 |
Cost and operating expenses | ||||
Cost of products sold | 17,279,000 | 7,891,000 | 30,047,000 | 19,068,000 |
Research and development | 14,249,000 | 13,176,000 | 28,956,000 | 25,082,000 |
Sales, general and administrative | 15,949,000 | 11,408,000 | 28,799,000 | 23,674,000 |
Total cost and operating expenses | 47,477,000 | 32,475,000 | 87,802,000 | 67,824,000 |
Loss from operations | (21,798,000) | (22,876,000) | (49,142,000) | (49,415,000) |
Other income (expense): | ||||
Interest income | 43,000 | 82,000 | 105,000 | 139,000 |
Interest expense | (9,303,000) | (9,704,000) | (21,486,000) | (18,062,000) |
Gain from change in fair value of derivative instruments | 35,775,000 | 20,934,000 | 38,114,000 | 42,612,000 |
Loss upon extinguishment of debt | (3,624,000) | (433,000) | (3,528,000) | (649,000) |
Other expense, net | (163,000) | (1,431,000) | (545,000) | (3,246,000) |
Total other income | 22,728,000 | 9,448,000 | 12,660,000 | 20,794,000 |
Income (loss) before income taxes | 930,000 | (13,428,000) | (36,482,000) | (28,621,000) |
Provision for income taxes | (310,000) | (138,000) | (269,000) | (253,000) |
Net income (loss) attributable to Amyris, Inc. | 620,000 | (13,566,000) | (36,751,000) | (28,874,000) |
Less deemed dividend (capital distribution to related parties) | (8,648,000) | (8,648,000) | ||
Less deemed dividend related to beneficial conversion feature on Series A preferred stock | (562,000) | (562,000) | ||
Less cumulative dividends on Series A and Series B preferred stock | (1,675,000) | (1,675,000) | ||
Net loss attributable to Amyris, Inc. common stockholders | $ (10,265,000) | $ (13,566,000) | $ (47,636,000) | $ (28,874,000) |
Net loss per share attributable to common stockholders: | ||||
Basic (in dollars per share) | $ (0.44) | $ (0.91) | $ (2.24) | $ (2) |
Diluted (in dollars per share) | $ (0.44) | $ (1.67) | $ (2.24) | $ (3.46) |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock: | ||||
Basic (in shares) | 23,155,874 | 14,874,135 | 21,226,013 | 14,426,247 |
Diluted (in shares) | 23,155,874 | 17,526,410 | 21,226,013 | 17,253,961 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Comprehensive loss: | ||||
Net loss attributable to Amyris, Inc. common stockholders | $ (10,265) | $ (13,566) | $ (47,636) | $ (28,874) |
Foreign currency translation adjustment, net of tax | (1,422) | 4,593 | (1,099) | 9,281 |
Comprehensive loss attributable to Amyris, Inc. common stockholders | $ (11,687) | $ (8,973) | $ (48,735) | $ (19,593) |
Condensed Consolidated Stateme6
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - USD ($) $ in Thousands | Series A Preferred Stock [Member]Preferred Stock [Member] | Series A Preferred Stock [Member]Common Stock [Member] | Series A Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series A Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series A Preferred Stock [Member]Retained Earnings [Member] | Series A Preferred Stock [Member]Noncontrolling Interest [Member] | Series A Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series A Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member]Preferred Stock [Member] | Series B Preferred Stock [Member]Common Stock [Member] | Series B Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series B Preferred Stock [Member]Retained Earnings [Member] | Series B Preferred Stock [Member]Noncontrolling Interest [Member] | Series B Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series B Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series B Preferred Stock [Member] | Preferred Stock [Member] | Common Stock [Member] | Preferred Stock Including Additional Paid in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Mezzanine Equity, Common Stock [Member] | Mezzanine Equity, Preferred Stock [Member] | Total |
Balance at Jun. 30, 2016 | $ 22 | $ 949,803 | $ (37,917) | $ (1,065,978) | $ (114) | $ 5,000 | $ (154,184) | ||||||||||||||||||||
Balance (in shares) at Dec. 31, 2015 | 13,742,019 | ||||||||||||||||||||||||||
Balance at Dec. 31, 2015 | $ 21 | 926,216 | (47,198) | (1,037,104) | (391) | (158,456) | |||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 547,992 | ||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | $ 1 | 8,637 | 8,638 | ||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments (in shares) | 566,049 | ||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments | 3,289 | 3,289 | |||||||||||||||||||||||||
Shares issued upon ESPP purchase | 123 | 123 | |||||||||||||||||||||||||
Issuance of contingently redeemable common stock (in shares) | 292,398 | ||||||||||||||||||||||||||
Issuance of contingently redeemable common stock | 5,000 | ||||||||||||||||||||||||||
Issuance of warrants with debt private placement | 3,971 | 3,971 | |||||||||||||||||||||||||
Acquisition of noncontrolling interest | (323) | 277 | (46) | ||||||||||||||||||||||||
Contribution upon restructuring of Fuels JV | 4,251 | 4,251 | |||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 9 | ||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock | |||||||||||||||||||||||||||
Shares issued from restricted stock settlement (in shares) | 64,305 | ||||||||||||||||||||||||||
Shares issued from restricted stock settlement | (201) | (201) | |||||||||||||||||||||||||
Shares issued upon ESPP purchase (in shares) | 15,122 | ||||||||||||||||||||||||||
Stock-based compensation | 3,840 | 3,840 | |||||||||||||||||||||||||
Foreign currency translation adjustment, net of tax | 9,281 | 9,281 | |||||||||||||||||||||||||
Net loss | (28,874) | (28,874) | |||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2016 | 15,227,894 | ||||||||||||||||||||||||||
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $634 (in shares) | 40,204 | ||||||||||||||||||||||||||
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $634 | 11,530 | ||||||||||||||||||||||||||
Balance at Jun. 30, 2017 | $ 3 | 1,012,906 | (42,003) | (1,171,189) | 937 | 5,000 | 12,830 | (199,346) | |||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 18,273,921 | ||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | $ 2 | 990,895 | (40,904) | (1,134,438) | 937 | 5,000 | (183,508) | ||||||||||||||||||||
Issuance of preferred stock for cash (in shares) | 22,140 | 30,700 | |||||||||||||||||||||||||
Issuance of preferred stock for cash | $ 1,300 | ||||||||||||||||||||||||||
Issuance of shares due to rounding from reverse stock split (in shares) | 6,473 | ||||||||||||||||||||||||||
Issuance of shares due to rounding from reverse stock split | |||||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock (in shares) | (18,840) | 2,990,374 | |||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock | |||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 2,257,786 | ||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | 14,154 | 14,154 | |||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments (in shares) | 1,246,165 | ||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments | $ 1 | 10,707 | 10,708 | ||||||||||||||||||||||||
Issuance of common stock for settlement of debt interest payments | 3,436 | 3,436 | |||||||||||||||||||||||||
Issuance of common stock for settlement of debt interest payments (in shares) | 400,967 | ||||||||||||||||||||||||||
Shares issued upon ESPP purchase | 69 | 69 | |||||||||||||||||||||||||
Deemed dividend upon conversion of debt into Series A and Series B preferred stock | (8,648) | $ (8,648) | |||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 134 | 133 | |||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock | |||||||||||||||||||||||||||
Shares issued from restricted stock settlement (in shares) | 79,841 | ||||||||||||||||||||||||||
Shares issued from restricted stock settlement | (391) | (391) | |||||||||||||||||||||||||
Shares issued upon ESPP purchase (in shares) | 16,759 | ||||||||||||||||||||||||||
Stock-based compensation | 2,684 | 2,684 | |||||||||||||||||||||||||
Foreign currency translation adjustment, net of tax | (1,099) | (1,099) | |||||||||||||||||||||||||
Net loss | $ (36,751) | $ (36,751) | |||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2017 | 74,204 | 25,272,420 |
Condensed Consolidated Stateme7
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) (Parentheticals) $ in Thousands | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Series A Preferred Stock [Member] | |
Issuance costs | $ 562 |
Series B Preferred Stock [Member] | |
Issuance costs | $ 634 |
Condensed Consolidated Stateme8
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Operating activities | ||
Net loss | $ (36,751,000) | $ (28,874,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 5,550,000 | 5,720,000 |
Loss on disposal of property, plant and equipment | (161,000) | (122,000) |
Stock-based compensation | 2,684,000 | 3,840,000 |
Amortization of debt discount and issuance costs | 7,637,000 | 7,415,000 |
Receipt of equity in connection with collaboration arrangements revenue | (2,660,000) | |
Loss upon extinguishment of debt | 3,528,000 | 649,000 |
Gain from change in fair value of derivative instruments | (38,115,000) | (42,612,000) |
Loss on foreign currency exchange rates | 63,000 | 1,083,000 |
Changes in assets and liabilities: | ||
Accounts receivable | (3,723,000) | (183,000) |
Related party accounts receivable | 214,000 | 587,000 |
Inventory | 409,000 | 1,910,000 |
Prepaid expenses and other assets | (4,220,000) | 1,695,000 |
Accounts payable | (1,739,000) | 1,190,000 |
Accrued and other liabilities | 8,392,000 | 8,132,000 |
Deferred revenue | (838,000) | 939,000 |
Deferred rent | (449,000) | (344,000) |
Net cash used in operating activities | (60,179,000) | (38,975,000) |
Investing activities | ||
Purchase of short-term investments | (3,966,000) | (2,366,000) |
Maturities of short-term investments | 3,895,000 | 2,585,000 |
Change in restricted cash | (982,000) | 7,000 |
Purchases of property, plant and equipment, net of disposals | (264,000) | (400,000) |
Net cash used in investing activities | (1,317,000) | (174,000) |
Financing activities | ||
Proceeds from sale of convertible preferred stock | 50,661,000 | |
Proceeds from exercises of common stock options, net of repurchase | 69,000 | 123,000 |
Employees' taxes paid upon vesting of restricted stock units | (110,000) | (201,000) |
Proceeds from issuance of contingently redeemable equity | 5,000,000 | |
Principal payments on capital leases | (764,000) | (506,000) |
Change in restricted cash related to contingently redeemable equity | 1,478,000 | (5,000,000) |
Proceeds from debt issued | 12,455,000 | 9,950,000 |
Proceeds from debt issued to related party | 25,000,000 | |
Principal payments on debt | (24,372,000) | (6,573,000) |
Net cash provided by financing activities | 39,417,000 | 27,793,000 |
Effect of exchange rate changes on cash and cash equivalents | 7,000 | 186,000 |
Net decrease in cash and cash equivalents | (22,072,000) | (11,170,000) |
Cash and cash equivalents at beginning of period | 27,150,000 | 11,992,000 |
Cash and cash equivalents at end of period | 5,078,000 | 822,000 |
Cash paid for interest | 4,526,000 | 3,735,000 |
Supplemental disclosures of non-cash investing and financing activities: | ||
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable | (1,189,000) | (521,000) |
Financing of equipment | 138,000 | 1,276,000 |
Financing of insurance premium under notes payable | (191,000) | (315,000) |
Issuance of common stock for settlement of debt principal and interest payments | 3,233,000 | 3,289,000 |
Issuance of convertible preferred stock upon conversion of debt | 40,204,000 | |
Issuance of common stock upon conversion of debt | 28,702,000 | 8,638,000 |
Interest capitalized to debt | 1,745,000 | 2,052,000 |
Non-cash investment in joint venture | 600,000 | |
Cancellation of debt and accrued interest on disposal of interest in affiliate | $ 4,252,000 |
Note 1 - The Company
Note 1 - The Company | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Amyris, Inc. (or the Company) is a leading industrial biotechnology company that is applying its technology platform to engineer, manufacture and sell high performance products into the Health and Nutrition, Personal Care and Performance Materials markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive chemical manufacturing processes. The Company has successfully used its technology to develop and produce at commercial volumes five July 17, 2003 April 15, 2010. The Company believes that industrial synthetic biology represents a third three Liquidity The Company expects to fund its operations for the foreseeable future with cash and investments currently on hand, with cash inflows from collaborations and grants, with cash contributions from product sales, and if needed, with new equity and debt financings. For the remainder of 2017 2018, The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations into 2018. June 30, 2017, $21.8 $1.2 $6.6 one not Our ability to continue as a going concern will depend, in large part, on our ability to achieve positive cash flows from operations during the next 12 2017 2018 If the Company is unable to continue as a going concern, it may may As of June 30, 2017, $26.0 $165.3 $13.3 twelve $11.2 Subsequent to June 30, 2017, $50 14, |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation and Principles of Consolidation The consolidated financial statements include the results of wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest with all significant intercompany accounts and transactions eliminated in consolidation. Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (or U.S. GAAP) for interim financial information and Article 10 X not June 30, 2017, three six June 30, 2017 2016, six June 30, 2017 2016. December 31, 2016 not 10 10 December 31, 2016. Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. not first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods reported. Actual results could differ from these estimates, and such differences may The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the six June 30, 2017 • ASU 2015 11, Inventory (Topic 330 • ASU 2016 06, Derivatives and Hedging (Topic 815 • ASU 2016 09, Compensation—Stock Compensation (Topic 718 None Recent Accounting Pronouncements Revenue Recognition May 2014, 2014 09, 606 , Revenue from Contracts with Customers 605, Revenue Recognition 2015 2016, first 2018. may first 2018. may not Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 first 2018. 2016 01 not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 Credit Losses of Financial Instruments June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 326 2016 13 first 2020 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 first 2018 Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 first 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not 2 not first 2018 When Changes to Share-based Payment Awards Must Be Accounted for as Modifications May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 not first 2018 |
Note 3 - Fair Value of Financia
Note 3 - Fair Value of Financial Instruments | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | 3. The inputs to the valuation techniques used to measure fair value are classified into the following categories: Level 1: Level 2: Level 3: not There were no June 30, 2017, Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 5,078 $ — $ — $ 5,078 Certificates of deposit 5,371 — — 5,371 Total financial assets $ 10,449 $ — $ — $ 10,449 Financial Liabilities Compound embedded derivative liability $ — $ — $ 56,222 $ 56,222 Currency interest rate swap derivative liability — — 2,384 2,384 Total financial liabilities $ — $ — $ 58,606 $ 58,606 As of December 31, 2016, Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Compound embedded derivative liability $ — $ — $ 4,135 $ 4,135 Currency interest rate swap derivative liability — — 3,343 3,343 Total financial liabilities $ — $ — $ 7,478 $ 7,478 The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The fair values of the currency interest rate swaps are based on the present value of expected future cash flows and assumptions about current interest rates and the Company's creditworthiness. The method of determining the fair value of the compound embedded derivative liabilities is described subsequently in this note. Market risk associated with the fixed and variable rate long-term loans payable, credit facilities and convertible notes relates to the potential reduction in fair value and negative impact to future earnings, from an increase in interest rates. Market risk associated with the compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes were recorded at carrying value, which was representative of fair value at the date of acquisition. The Company estimates the fair value of loans payable and credit facilities using market observable inputs (Level 2 3 June 30, 2017 $16.6 $49.8 $99.0 June 30, 2017 $13.4 $32.6 $95.8 The following table provides a reconciliation of the beginning and ending balances for the compound embedded derivative liabilities measured at fair value using significant unobservable inputs (Level 3 2017 Balance at January 1 $ 4,135 Gain from change in fair value of derivative liabilities (in statements of operations) (32,210 ) Additions 93,675 Derecognition on extinguishment or conversion (9,378 ) Balance at June 30 $ 56,222 The compound embedded derivative liabilities represent the fair value of the equity cash warrants, conversion options and "make-whole" provisions of the May 2017 May 2017 2014 144A 2015 144A 5, June 30, 2017 December 31, 2016, $56.2 $4.1 The market-based assumptions and estimates used in applying a Monte Carlo simulation approach and Black-Scholes-Merton option value approach for valuing the compound embedded derivative liabilities include amounts in the following ranges/amounts: June 30, 2017 May 11, 2017 December 31, 2016 Risk-free interest rate 1.29% - 1.93% 1.93% 0.55% - 1.31% Risk-adjusted yields 4.50% - 28.93% — 12.80% - 22.93% Stock-price volatility 45% - 80% 80% 45% Probability of change in control 5% 5% 5% Stock price $3.18 $4.95 $0.73 Credit spread 3.15% - 27.57% — 11.59% - 21.64% Estimated conversion dates 2017 - 2022 2017 - 2022 2017 - 2019 Changes in valuation assumptions can have a significant impact on the valuation of the embedded derivative liabilities. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. Certain of the Convertible Notes also include conversion price adjustment features whereby, for example, issuances of equity or equity-linked securities by the Company at prices lower than the conversion price then in effect for such notes result in a reset or adjustment of the conversion price of such notes, which increases the value of the embedded derivative liabilities. See Note 5, On April 21, 2017, 850,115 $3.2 40%, 0.92%, zero 45%. In June 2012, 5, R$22.0 US$6.7 June 30, 2017 3.94%. Changes in the fair value of the compound embedded derivative liabilities are recognized in “Gain from change in fair value of derivative instruments" in the condensed consolidated statements of operations are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, Type of Derivative Contract 2017 2016 2017 2016 Compound embedded derivative liabilities $ 35,814 $ 19,659 $ 36,315 $ 40,492 Currency interest rate swaps (39 ) 1,275 1,799 2,120 Total gain from change in fair value of derivative instruments $ 35,775 $ 20,934 $ 38,114 $ 42,612 |
Note 4 - Balance Sheet Componen
Note 4 - Balance Sheet Components | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 4. Inventories Inventories are stated at the lower of cost or net realizable value and are comprised of the following (in thousands): June 30, December 31, Raw materials $ 2,937 $ 3,159 Work-in-process 1,379 1,848 Finished goods 1,413 1,206 Inventories $ 5,729 $ 6,213 Property, Plant and Equipment, net Property, plant and equipment, net is comprised of the following (in thousands): June 30, December 31, 2016 Machinery and equipment $ 84,785 $ 82,688 Leasehold improvements 38,770 38,785 Computers and software 9,619 9,585 Buildings 4,630 4,699 Furniture and office equipment 2,324 2,333 Vehicles 133 164 Land 460 460 Construction in progress 367 2,216 141,088 140,930 Less: accumulated depreciation and amortization (91,785 ) (87,195 ) Property, plant and equipment, net $ 49,303 $ 53,735 Property, plant and equipment, net includes $3.4 $3.1 June 30, 2017 December 31, 2016, $0.3 $0.6 June 30, 2017 December 31, 2016, Depreciation and amortization expense, including amortization of assets under capital leases was $2.7 $2.8 three June 30, 2017 2016, $5.4 $5.7 six June 30, 2017 2016, Other Assets (noncurrent) Other assets are comprised of the following (in thousands): June 30, December 31, Recoverable taxes from Brazilian government entities $ 15,443 $ 13,723 Cost-method investment 3,233 — Deposits on property and equipment, including taxes 909 291 Other 1,198 1,450 Total other assets $ 20,783 $ 15,464 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following (in thousands): June 30, December 31, Withholding tax related to conversion of related party notes $ 1,370 $ 1,370 Professional services 5,943 6,876 SMA relocation accrual 3,587 3,641 Accrued interest 4,133 4,847 Tax-related liabilities 2,741 2,610 Accrued vacation 2,274 2,034 Payroll and related expenses 3,512 4,310 Deferred rent, current portion 1,122 1,111 Contractual obligations to contract manufacturers 2,698 — Other 1,895 2,389 Total accrued and other current liabilities $ 29,275 $ 29,188 |
Note 5 - Debt and Mezzanine Equ
Note 5 - Debt and Mezzanine Equity | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 5. Debt and mezzanine equity are comprised of the following (in thousands): June 30, 2017 December 31, 2016 Senior secured loan facility $ 27,999 $ 27,658 BNDES credit facility 577 1,172 FINEP credit facility 534 696 Guanfu credit facility 20,645 19,564 Total credit facilities 49,755 49,090 Convertible notes 54,471 78,981 Loans payable 14,592 26,527 Related party convertible notes 44,499 42,754 Related party loan payable 2,000 29,691 Total debt 165,317 227,043 Less: current portion (13,285 ) (59,155 ) Long-term debt, net of current portion $ 152,032 $ 167,888 Mezzanine equity Contingently redeemable common stock $ 5,000 $ 5,000 Convertible preferred stock $ 12,830 $ — Senior Secured Loan Facility In March 2014, $25.0 June 2014, March 2015 November 2015 $30,960,000, $15,960,000 $1,450,000 In June 2016, 8, October 2016, fourth $1 January 11, 2017, October 15, 2018 No January 2017, fifth $3 As of June 30, 2017, $27.8 $0.6 may FINEP Credit Facility As of June 30, 2017 December 31, 2016, R$1.8 US$0.5 R$2.3 US$0.7 R$6.0 US$1.8 June 30, 2017 Guanfu Credit Facility On October 26, 2016, $25.0 three November 2016, December 31, 2016, $25.0 five 10% March 31, 2017. may, 100% Upon the occurrence of certain specified events of default under the Guanfu Credit Facility, the Company will grant to Guanfu an exclusive, royalty-free, global license to certain intellectual property useful in connection with Guanfu’s existing commercial relationship with the Company. In addition, in the event the Company fails to pay interest or principal under the Guanfu Note within ten 90% 90 two Convertible Notes Fidelity In February 2012, $25.0 3% March 1, 2017 $106.023 October 2015, $57.6 “2015 144A $8.8 $9.7 December 28, 2016, $19.1 2015 144A 1:1.25 i.e. $1.00 $1.25 2015 144A 1933, January 11, 2017. $19.1 2015 144A not 2015 144A $0.1 first 2015 144A fourth October 15, 2018. fourth 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A $72.0 $24.7 2014 144A $9.7 October 2015, $57.6 “2015 144A $18.3 $22.9 2014 144A 2014 144A 6.50% May 15 November 15 2014 144A May 15, 2019, 2014 144A 17.8073 $1,000 2014 144A $56.16 5, 2014 144A 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A 2015 144A $54.4 $18.3 $22.9 2014 144A $8.8 $9.7 2015 144A 2015 144A 9.50% April 15 October 15 2015 144A April 15, 2016 October 15, 2016 April 15, 2017 2015 144A April 15, 2019 The 2015 144A 48.3395 $1,000 2015 144A June 6, 2017, $20.69 2015 144A April 15, 2019), 0.75%. may 92.5% 10 June 30, 2017, January 2017, $19.1 2015 144A 2015 144A $15.3 2015 144A 2015 144A not 2015 144A not 2015 144A 2015 144A 19.99% December 28, 2016 ( 2015 144A 2015 144A May 2016 In May 2016, May 2016 $15.0 May 2016 Pursuant to the May 2016 May 2016 three May 2016, September, 2016 October 2016 $14.9 The May 2016 October 2016. December 2016 April 2017 On December 1, 2016, December 2016 $10.0 December 2016 $9.9 December 2016 May 2017. On April 13, 2017, April 2017 $15.0 April 2017 April 2017 first third April 2017 April 2017 On April 17, 2017, April 2017 $7.0 $7 $6.9 $7 May 2017. On May 2, 2017, April 2017 December 2016 April 2017 December 2016 April 2017 December 2016 April 2017 may 10% 20% 80% December 2016 April 2017 five 70% five On June 30, 2017, April 2017 $3.0 $3 $3.0 $3 $3 $3 10 14, The Amended Notes are general unsecured obligations of the Company. Unless earlier converted or redeemed, the Amended Notes will mature on or about the 18 The Amended Notes are payable in monthly installments, in either cash at 118% not 50% $200,000. The Amended Notes contain customary terms and covenants, including certain events of default after which the holders may 118% In the event of a Fundamental Transaction (as defined in the Amended Notes), holders of the Amended Notes may 118% The Company has the right to redeem the Amended Notes for cash, in whole, at any time, or in part, from time to time, at a redemption price equal to 118% The Amended Notes are convertible from time to time, at the election of the holders, into shares of common stock at an conversion price of $28.50 Notwithstanding the foregoing, the holders will not not 4.99% not 9.99%, not 61 3,792,779 April 2017 April 2017 218,817 For as long as they hold Amended Notes or shares of common stock issued under the Amended Notes, the holders may not $15.75 $15.00, may not As of June 30, 2017, $19.1 December 31, 2016, December 2016 $9.9 See Note 14, June 30, 2017. Related Party Convertible Notes Total R&D Convertible Notes In July 2012 December 2013, $105.0 1.5% March 2017 ( January 2015 In July 2015, $5.0 $70 2.0 5, In March 2016, one 75% 25% $1.3 $2.8 July 29, 2015) 50,000, $5.0 $3.7 25% $4.2 As of June 30, 2017 December 31, 2016, $3.7 $3.7 In February 2017, March 1, 2017 May 15, 2017. May 2017, second May 15, 2017 March 31, 2018, ( 1.5% 12.0%, May 16, 2017, December 31, 2017 $46.20 10 August 2013 In August 2013, August 2013 $73.0 August 2013 24 In October 2013, $35.0 February 2, 2014 5.5% October 16, 2013 first August 2013 In October 2013, August 2013 first August 2013 $7.6 first $9.2 first October 2013, first August 2013 $51.8 $7.6 $44.2 $35.0 $9.2 $35.0 $9.2 $19.9 sixty October 16, 2018) $2.44 15% 60 August 7, 2013, 5% six six June 30, 2017, may six In December 2013, August 2013 $3.0 second August 2013 January 2014, $34.0 second August 2013 $25.0 $3.0 $6.0 $6.0 $9.4 sixty January 15, 2019). 10%, twelve June 30, 2017, The conversion price of the Tranche I Notes and Tranche II Notes is approximately $7.425 June 30, 2017. As of June 30, 2017 December 31, 2016, $22.1 $21.8 $0.0 $0.0 5, Loans Payable In July 2012, July 2012 July 2012 R$52.0 US$15.7 June 30, 2017 R$68.0 US$20.6 June 30, 2017 July 2012 R$52.0 US$15.7 June 30, 2017 July 15, 2022 5.5% 30 first two August 15, 2014, June 30, 2017 December 31, 2016, $10.0 $11.1 Exchange (Debt Conversion - Related Party Transaction) In July 2015, $71.0 July 29, 2015) $70.0 $34.50 $39.2 December 31, 2015. Under the Exchange Agreement, Total also received the following warrants, each with a five • A warrant to purchase 1,261,612 • A warrant to purchase 1,333,334 March 1, 2017, • Additionally, under the Exchange Agreement, Temasek received the following warrants, each with a ten • A warrant to purchase 978,525 • A warrant exercisable for that number of shares of the Company’s common stock equal to ( 1 may 133,334, 30.6% 69.4% 2 may 13.3% 86.7% • A warrant exercisable for that number of shares of the Company’s common stock equal to 58,690 133,334 58,690 The Temasek Exchange Warrant, the Temasek Funding Warrant and the Temasek R&D Warrant are referred to herein as the “Temasek Warrants” and the Temasek Warrants and the Total Warrants are hereinafter collectively referred to as the “Exchange Warrants”. In addition to the grant of the Exchange Warrants, a warrant issued by the Company to Temasek in October 2013 2013 66,667 2013 $0.01 In February May 2016, 164,169 May 2017, 1,125,755 As of March 1, 2017, not March 1, 2017 As of June 30, 2017, 2013 846,683 June 30, 2017. 1,289,924 June 30, 2017. $0.15 June 30, 2017. Maturity Treatment Agreement At the closing of the Exchange, the Company, Total and Temasek also entered into a Maturity Treatment Agreement, dated as of July 29, 2015, 2014 144A not not $10.0 2014 144A $25.0 $9.7 2014 144A $15.3 May 2017, 2014 144A no February 2016 On February 12, 2016 February 15, 2016, $18.0 $2.0 February 2016 171,429 19,048 $0.15 February 2016 $20.0 $16.0 February 2016 152,381 $2.0 February 2016 19,048 $2.0 February 2016 19,048 The February 2016 February 12, 2016, February 2016 13.50% May 15, 2017. May 2017, February 2016 February 2016 May 2017, first February 2016 May 15, 2017 November 15, 2017. As of June 30, 2017, February 2016 none February 2016 February 2016 $0.15 June 30, 2017. As of June 30, 2017, February 2016 $2.0 June 2016 On June 24, 2016, $5.0 June 2016 June 2016 13.50% June 2016 May 15, 2017. May 2017, June 2016 June 2016 October 2016 On October 21 October 27, 2016, $6.0 $8.5 October 2016 October 2016 October 2016 13.50% October 2016 May 15, 2017. May 2017, October 2016 October 2016 October 2016 May 2017, Salisbury Note In December 2016, $3.5 5% 13 January 1, 2017 ( 5% 5 January 2017, Nikko Note In December 2016, 7, $3.9 5% 13 January 1, 2017 ( 5% 5 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may Future minimum payments under the debt agreements as of June 30, 2017 Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Related Party Loans Payable Credit Facility Total 2017 (remaining six months) $ 558 $ 4,123 $ 1,426 $ 2,487 $ 3,480 $ 12,074 2018 20,448 8,636 5,268 — 33,696 68,048 2019 34,913 68,097 2,665 — 2,577 108,252 2020 — — 2,559 — 2,500 5,059 2021 — — 2,451 — 27,396 29,847 Thereafter — — 4,057 — — 4,057 Total future minimum payments 55,919 80,856 18,426 2,487 69,649 227,337 Less: amount representing interest (1) (11,421 ) (26,385 ) (3,834 ) (487 ) (19,893 ) (62,020 ) Present value of minimum debt payments 44,498 54,471 14,592 2,000 49,756 165,317 Less: current portion (3,700 ) (1,517 ) (5,186 ) (2,000 ) (882 ) (13,285 ) Noncurrent portion of debt $ 40,798 $ 52,954 $ 9,406 $ — $ 48,874 $ 152,032 ( 1 Bill & Melinda Gates Foundation Investment (Mezzanine Equity) On May 10, 2016, 292,398 $17.10 $5.0 not 2017. third 10%. June 30, 2017, $5.0 not May 2017 On May 8, 2017 May 31, 2017, May 2017 22,140 17.38% $0.0001 70,904 17.38% $0.0001 $0.0001 14,768,380 May 2017 May 2017 May 2017 The May 2017 May 11, 2017 ( May 11 May 31, 2017, May 2017 $50.2 May 2017 $22,140,000, May 2017 $30,700,000 $40.2 $33.1 The May 2017 May 2017 may not July 31, 2017 may not one May 11 Series A Preferred Stock (Permanent Equity) Each share of Series A Preferred Stock has a stated value of $1,000 $17.25 not October 9, 2017, 90th Dividends, at a rate per year equal to 17.38% tenth October 15 April 15, October 15, 2017, tenth $1,738 $1,000 not first Unless and until converted into common stock in accordance with its terms, the Series A Preferred Stock has no In the event of a fundamental transaction, the holders of the Series A Preferred Stock will have the right to receive the consideration receivable as a result of such fundamental transaction by a holder of the number of shares of Common Stock for which the Series A Preferred Stock is convertible immediately prior to such fundamental transaction (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted to Common Stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. Notwithstanding the foregoing, the holders (other than the Designated Holder (as defined below)) will not not 4.99% not 9.99%, not 61 The Series A Preferred Stock were offered and sold pursuant to a prospectus filed with the SEC on April 9, 2015 May 8, 2017, 3 No. 333 203216 April 15, 2015. On May 8, 2017, 17.38% The Series A preferred stock has been classified as permanent equity, as the Company controls all actions or events required to settle the Optional and Mandatory Conversion feature in shares. The make whole payment was determined to be an embedded derivative requiring bifurcation and separate recognition as a derivative liability recognized at its fair value as of the issuance date with subsequent changes in fair value recorded in earnings until the Series A preferred stock is converted into common stock and the make whole payment is paid or until the make whole payment is paid through declared dividends or cash. The Series A preferred stock also contains a beneficial conversion feature which has been recognized up to the amount of proceeds allocated to the preferred stock ( $0.6 $0.0 As of June 30, 2017, 18,840 $9.4 Series B Preferred Stock (Mezzanine Equity) The Series B Preferred Stock has substantially identical terms to the Series A Preferred Stock (as described above), except that the issuance of the shares of common stock issuable upon conversion of the Series B Preferred Stock or as payment of dividends or the Make-Whole Payment on the Series B Preferred Stock (or the Series B Conversion Shares) was initially subject to the Stockholder Approval (as defined below). The Series B Preferred Stock was accounted for as Mezzanine equity as the embedded conversion options are not The investors of the Series B Preferred Stock included related parties affiliated with certain members of the Company’s Board of Directors (or the Affiliated Investors). Foris exchanged an aggregate principal amount of $27.0 February 12, 2016, June 24, 2016 October 21, 2016, 30,728.589 May 2017 4,877,386 $2.0 February 15, 2016, 2,333.216 May 2017 370,404 $8.6 Certain investors of the Series B Preferred Stock included holders of certain of the Company’s existing indebtedness, including the 2014 144A 2015 144A $3.4 2014 144A $3.7 2015 144A May 2017 May 2017 May 11 $1.9 The remaining Series B preferred stock was purchased in exchange for cash proceeds of $30.7 no not A derivative liability has been recognized at fair value on the date of issuance for the make whole payment in the amount of $34.7 June 30, 2017 $0.8 May 2017 Pursuant to the May 2017 $7.80 June 30, 2017, 50% 7,384,190 $9.30 June 30, 2017, 7,384,190 three In addition, the Company issued to each investor a warrant, with an exercise price of $0.0015 June 30, 2017 ( three $6.30 May 2017 The exercise of the May 2017 May 2017 five May 2017 The Cash Warrants are freestanding financial instruments that are accounted for as derivative liabilities and recognized at their fair value on the date of issuance of $39.5 May 2022. The full-ratchet anti-dilution protection of the Cash Warrants are also freestanding financial instruments that have been accounted for as derivative liabilities and recognized at their fair value on the date of issuance of $4.4 May 2020. Stockholder Approval Pursuant to the May 2017 May 2017 May 2017 July 10, 2017, July 7, 2017. Registration Rights Pursuant to the May 2017 30 3 not 3 May 2017 181 no May 2017 May 2017 144 August [4], 2017, 3 May 2017 May 2017 Stockholder Agreement In connection with the May 2017 May 11, 2017, one 25,000 3,968,116 May 2017 $25,000,000. one May 18, 2017, no 4.5% not 60 2018. Pursuant to the Stockholder Agreement, the Designated Holder agreed not May 2017 May 2017 one third first May 2017 May 2017 three no not, 33% May 2017 not 13 3 1934 Pursuant to the Stockholder Agreement, the Company and the Designated Holder agreed to negotiate in good faith during the 90 no $25 no $30 90 second not 90 December 31, 2017, ( first $5 not 14, Series C Preferred Stock Exchange In connection with the transactions contemplated by the May 2017 May 8, 2017, May 2017 1,394,706 20,921 $0.0001 not May 2017 May 11, 2017. Each share of Series C Preferred Stock has a stated value of $1,000 $15 The Series C Preferred Stock is entitled to participate with the common stock on an as-converted basis with respect to any dividends or other distributions to holders of common stock. The Series C Preferred Stock shall vote together as one In the event of a fundamental transaction, the holders of the Series C Preferred Stock will have the right to receive the consideration receivable as a result of such fundamental transaction by a holder of the number of shares of common stock for which the Series C Preferred Stock is convertible immediately prior to such fundamental transaction (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series C Preferred stock shall be entitled to receive out of the assets of the Company an amount equal to the greater of (i) the par value of each share of Series C Preferred Stock, plus any accrued and unpaid dividends or other amounts due on such Series C Preferred Stock, prior to any distribution or payment to the holders of common stock or (ii) the amount that a holder would receive if the Series C Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. The shares of Series C Preferred Stock automatically converted to common stock on June 6, 2017 15:1 no |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Commitments Contingencies and Guarantees [Text Block] | 6. Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities and capital leases include leased equipment (see Note 4, February 2031. $1.4 $1.4 three June 30, 2017 2016, $2.8 $2.7 six June 30, 2017 2016, Future minimum payments under the Company's lease obligations as of June 30, 2017 Years ending December 31: Capital Operating Total Lease 2017 (remaining six months) $ 530 $ 3,406 $ 3,936 2018 106 6,889 6,995 2019 22 6,776 6,798 2020 — 7,006 7,006 2021 — 7,242 7,242 Thereafter — 10,958 10,958 Total future minimum payments $ 658 $ 42,277 $ 42,935 Less: amount representing interest (27 ) Present value of minimum lease payments 631 Less: current portion (598 ) Long-term portion $ 33 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officers or directors are serving in their official capacities. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no June 30, 2017 December 31, 2016. Purchase Obligations As of June 30, 2017 December 31, 2016, $0.9 $0.8 $0.6 $0.6 Production Cost Commitment As of June 30, 2017, not three six June 30, 2017 three $10 Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not The Company has levied indirect taxes on sugarcane-based biodiesel sales by Amyris Brasil to customers in Brazil based on advice from external legal counsel. In the absence of definitive rulings from the Brazilian tax authorities on the appropriate indirect tax rate to be applied to such product sales, the actual indirect rate to be applied to such sales could differ from the rate we levied. In April 2017, March 2, 2017 April 17, 2017. March 2, 2017 12b 25 April 3, 2017. In June 2017, Gutierrez v John G. Melo et al No. 665782, not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one |
Note 7 - Joint Ventures and Non
Note 7 - Joint Ventures and Noncontrolling Interest | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 7. Aprinnova JV The Company is a 50% The table below reflects the carrying amount of the Aprinnova JV's assets and liabilities, for which the Company is the primary beneficiary at June 30, 2017: (In thousands) June 30, 2017 December 31, 2016 Assets $ 32,541 $ 30,778 Liabilities 2,221 333 The change in the Company's noncontrolling interest in Aprinnova JV for the six June 30, 2017 2016, 2017 2016 Balance at January 1 $ 937 $ — Acquisition of noncontrolling interest — 114 Balance at June 30 $ 937 $ 114 |
Note 8 - Significant Agreements
Note 8 - Significant Agreements | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 8. Research and Development Activities Firmenich Collaboration Agreement In March 2013, November 2010 10 3 twelve The Firmenich Collaboration Agreement provided for annual, up-front funding to the Company by Firmenich of $10.0 first three $10.0 March 2013, 2014 2015. $5.0 four June 2017, four $2.1 $1.3 three June 30, 2017 2016, $3.2 $4.3 six June 30, 2017 2016, not Under the Firmenich Collaboration Agreement, the parties agreed to jointly select target compounds, subject to final approval of compound specifications by Firmenich. During the development phase, the Company would be required to provide labor, intellectual property and technology infrastructure and Firmenich would be required to contribute downstream polishing expertise and market access. The Firmenich Collaboration Agreement provides that the Company will own research and development and strain engineering intellectual property, and Firmenich will own blending and, if applicable, chemical conversion intellectual property. Under certain circumstances, such as the Company’s insolvency, Firmenich would gain expanded access to the Company’s intellectual property. The Firmenich Collaboration Agreement contemplates that, following development of flavors and fragrances compounds, the Company will manufacture the initial target molecules for the compounds and Firmenich will perform any required downstream polishing and distribution, sales and marketing. The Firmenich Collaboration Agreement provides that the parties will mutually agree on a supply price for each compound developed under the agreement and, subject to certain exceptions, will share product margins from sales of each such compound on a 70/30 70% $15.0 50/50. one $2.5 not June 30, 2017. In September 2014, $0.9 $2.6 three June 30, 2017 2016, $2.1 $4.6 six June 30, 2017 2016, In December 2016, third ten third 2016 Kuraray Collaboration Agreement In July 2011, March 2014, two $4.0 two $2.0 first April 30, 2014 second April 30, 2015. March 2015, December 31, 2016 second $2.0 March 31, 2015. November 2016 #3 December 31, 2018 $1.0 two $500,000 January 15, 2017 January 15, 2018, Under this agreement, the Company recognized (i) collaboration revenues of $0.1 $0.4 three June 30, 2017 2016, $0.3 $0.8 six June 30, 2017 2016, $1.9 $0.2 three June 30, 2017 2016, $3.6 $0.2 six June 30, 2017 2016, DARPA Technology Investment Agreement In September 2015, 2015 five 2015 2015 2015 2015 $35.0 4 $15.5 four may, 2015 not The Company recognized collaboration revenues of $ 4.7 $2.3 three June 30, 2017 2016, $5.7 $3.5 six June 30, 2017 2016, Nenter Agreements In April 2016, six 2017, $2.4 December 31, 2020 5 no July 1, 2020, The Company recognized revenues from product sales under the Nenter Supply Agreement of $6.6 zero three June 30, 2017 2016, $8.9 $0.03 six June 30, 2017 2016, In October 2016, May 2017 5, May 8, 2017, October 26, 2016, $2.5 June 22, 2017. 40 June 28, 2017. Givaudan Agreements In June 2016, $12.0 $3.0 June 30, 2016. $3.0 June 2016, December 2016 June 2017, Pursuant to the Givaudan Collaboration Agreement, the Company agreed to grant to Givaudan an exclusive license to the intellectual property that the Company generates under the agreement. Such license will include the rights to make, use and sell compounds in the active cosmetics and flavors fields, and is subject to certain ‘claw back’ rights by the Company if a compound is not Subject to certain rights granted to a third not third 2 The Company recognized collaboration revenues under the Givaudan Collaboration Agreement of $1.5 $0 three June 30, 2017 2016, $3.0 $0 six June 30, 2017 2016, Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, $20.0 two ten first $15.0 July 25, 2016. second $5.0 not June 30, 2017, no In addition, pursuant to the Initial Ginkgo Agreement, (i) the Company and Ginkgo agreed to pursue the negotiation and execution of a detailed definitive partnership and license agreement setting forth the terms of a commercial partnership and collaboration arrangement between the parties (Ginkgo Collaboration), (ii) the Company agreed to issue to Ginkgo an option to purchase 333,334 $7.50, one October 31, 2016 x 5, On August 6, 2016, 333,334 $7.50 one On September 30, 2016, third not March 30, 2017, $5.0 second not June 30, 2017, no Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products will be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Ginkgo Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. The initial term of the Ginkgo Collaboration Agreement is three one not 90 18 30 In April 2017, $3 5, The Company recognized zero zero three June 30, 2017 June 30, 2016, zero zero six June 30, 2017 June 30, 2016, June 30, 2017, $1.5 Blue California Agreements In December 2016, $10 March 31, 2017, April 17, 2017, April 2017, one $10 April 21, 2017, 850,115 The Company recognized revenues of $2.7 $0 three June 30, 2017 2016, $2.7 $0 six June 30, 2017 2016, Financing Agreements At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 No. 333 203216 April 15, 2015. 415 one may not 3.0% no During the six June 30, 2017, not $50.0 See Note 14, June 30, 2017. |
Note 9 - Goodwill and Intangibl
Note 9 - Goodwill and Intangible Assets | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 9. The following table presents the components of the Company's intangible assets (in thousands): June 30, 2017 December 31, 2016 Useful Life in Years Gross Carrying Amount Accumulated Amortization Net Carrying Value Gross Carrying Amount Accumulated Amortization Net Carrying Value In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 The Company has a single reportable segment. Consequently, all of the Company's goodwill is attributable to that single reportable segment. |
Note 10 - Stock-based Compensat
Note 10 - Stock-based Compensation | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 10. The Company’s stock option activity and related information for the six June 30, 2017 Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2016 875,021 $ 55.20 Options granted 192,569 $ 6.94 — $ — Options exercised (133 ) $ 4.20 — $ — Options forfeited (70,182 ) $ 27.03 — $ — Outstanding - June 30, 2017 997,275 $ 47.87 7.01 $ 440 Vested and expected to vest after June 30, 2017 895,140 $ 51.99 6.76 $ 310 Exercisable at June 30, 2017 539,738 $ 76.14 5.36 $ — The Company’s restricted stock units (or "RSUs") and restricted stock activity and related information for the six June 30, 2017 RSUs Weighted- Weighted Average Outstanding - December 31, 2016 454,923 $ 17.48 Awarded 354,117 $ 6.74 — Vested (106,833 ) $ 22.33 — Forfeited (35,871 ) $ 13.76 — Outstanding - June 30, 2017 666,336 $ 11.20 1.64 Expected to vest after June 30, 2017 501,550 $ 11.56 1.45 Stock-based Compensation Expense Stock-based compensation expense related to options and restricted stock units granted to employees and non-employees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 441 $ 485 $ 925 $ 976 Sales, general and administrative 597 1,304 1,759 2,864 Total stock-based compensation expense $ 1,038 $ 1,789 $ 2,684 $ 3,840 As of June 30, 2017, $8.5 2.9 Stock-based compensation expense for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on their fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Expected dividend yield — % — % — % — % Risk-free interest rate 1.82 % 1.4 % 1.82 % 1.4 % Expected term (in years) 5.38 6.16 5.38 6.16 Expected volatility 85.7 % 72.5 % 85.7 % 72.5 % |
Note 11 - Related Party Transac
Note 11 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 11. Related Party Financings See Note 5, three six June 30, 2017. 14, June 30, 2017. As of June 30, 2017 December 31, 2016, $46.3 $72.4 $5.1 $6.7 The fair value of the derivative liability in connection with the related party convertible notes and preferred stock as of June 30, 2017 December 31, 2016 $41.0 $0.8 three June 30, 2017 2016, $22.3 $3.9 six June 30, 2017 2016, $20.0 $8.4 3, Related Party Revenues During the three six June 30, 2017 2016, $0.1 June 30, 2017 December 31, 2016, $0.6 $0.8 Joint Venture with Cosan and American Refining Group In June 2017, $60,000 Pilot Plant Agreements with Total The Company and Total are parties to two five April 4, 2014 June 30, 2017 December 31, 2016, $1.4 $1.8 |
Note 12 - Income Taxes
Note 12 - Income Taxes | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 12. The Company recorded income tax provisions of $0.3 $0.1 three June 30, 2017 2016, $0.3 $0.3 six June 30, 2017 2016, no |
Note 13 - Net Loss Per Share At
Note 13 - Net Loss Per Share Attributable to Common Stockholders | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 13. Basic net loss per share attributable to common stockholders is computed by dividing the Company’s net loss attributable to Amyris, Inc. common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units, common stock warrants and convertible promissory notes using the treasury stock method or the as-converted method, as applicable. For the three six June 30, 2017, The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net income (loss) $ 620 $ (13,566 ) $ (36,751 ) $ (28,874 ) Less deemed dividend (capital distribution to related parties) (8,648 ) — (8,648 ) — Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) — (562 ) — Less cumulative dividends on Series A and Series B preferred stock (1,675 ) — (1,675 ) — Net loss attributable to Amyris, Inc. common stockholders, basic (10,265 ) (13,566 ) (47,636 ) (28,874 ) Interest on convertible debt — 1,591 — 3,501 Accretion of debt discount — 1,846 — 3,479 Loss (gain) from change in fair value of derivative instruments — (19,116 ) — (37,803 ) Net loss attributable to Amyris, Inc. common stockholders, diluted $ (10,265 ) $ (29,245 ) $ (47,636 ) $ (59,697 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 23,155,874 14,874,135 21,226,013 14,426,247 Basic loss per share $ (0.44 ) $ (0.91 ) $ (2.24 ) $ (2.00 ) Weighted-average shares of common stock outstanding 23,155,874 14,874,135 21,226,013 14,426,247 Effect of dilutive convertible promissory notes — 2,652,275 — 2,827,714 Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 23,155,874 17,526,410 21,226,013 17,253,961 Diluted loss per share $ (0.44 ) $ (1.67 ) $ (2.24 ) $ (3.46 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock because including them would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Period-end stock options to purchase common stock 997,275 948,603 997,275 948,603 Convertible promissory notes (1) 6,270,734 4,489,743 6,270,734 4,489,743 Period-end common stock warrants 16,871,700 193,429 16,871,700 193,429 Period-end restricted stock units 666,336 520,602 666,336 520,602 Total 24,806,045 6,152,377 24,806,045 6,152,377 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 14 - Subsequent Events
Note 14 - Subsequent Events | 6 Months Ended |
Jun. 30, 2017 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 14. August 2017 DSM Purchase Agreement On August 2, 2017, 25,000 August 2017 3,968,116 August 2017 August 2017 August 2017 4 2 August 2017 On August 7, 2017, 25,000 August 2017 $24.8 August 7, 2017, August 2017 5, The DSM Purchase Agreement includes customary representations, warranties and covenants of the parties. In addition, the Company, subject to certain exceptions, (i) may not October 31, 2017, ( may not May 11, 2018 may not DSM Warrants At the August 2017 $6.30 3,968,116 August 2017 August 2017 three In addition, at the DSM Closing, the Company issued to DSM a warrant, with an exercise price of $0.0001 August 2017 $6.30 August 2017 $0.10 The effectiveness of the anti-dilution adjustment provision of the August 2017 August 2017 August 2017 August 2017 five August 2017 The August 2017 4 2 Registration Pursuant to the DSM Purchase Agreement, the Company on August 4, 2017 3 August 2017 August 2017 Amended and Restated Stockholder Agreement In connection with the August 2017 May 11, 2017 two one 10% no 4.5% August 2017 Following the August 2017 not 90 August 2017 first August 2017 $5 not $25 Vivo Purchase Agreement On August 2, 2017, August 2017 August 2017 2,826,711 $4.26 12,958 $0.0001 August 2017 5,575,118 August 2017 August 2017 August 2017 4 2 August 2017 On August 3, 2017, 2,826,711 12,958 August 2017 $24.8 August 3, 2017, The August 2017 August 2017 may not Series D Preferred Stock Each share of Series D Preferred Stock has a stated value of $1,000 August 2017 $4.26 Prior to declaring any dividend or other distribution of its assets to holders of common stock, the Company shall first $0.0001 Unless and until converted into common stock in accordance with its terms, the Series D Preferred Stock has no In the event of a Fundamental Transaction, the holders of the Series D Preferred Stock will have the right to receive the consideration receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series D Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to whether such Series D Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. A Fundamental Transaction is defined in the Certificate of Designation of Preferences, Rights and Limitations relating to the Series D Preferred Stock as any of the following: (i) merger with or consolidation into another legal entity; (ii) sale, lease, license, assignment, transfer or other disposition of all or substantially all of the Company’s assets in one 50% 50% Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series D Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series D Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series D Preferred Stock is convertible at such time) , which amount shall be paid pari passu with all holders of common stock. Notwithstanding the foregoing, the holders will not not 9.99% August 2017 may August 2017 not 61st no not On August 3, 2017, Vivo Warrants At the August 2017 $6.39 5,575,118 August 2017 August 2017 three August August 2017 In addition, at the August 2017 $0.0001 August 2017 $4.26 The effectiveness of the anti-dilution adjustment provisions of the August 2017 August 2017 August 2017 August 2017 five August 2017 August 2017 August 2017 The August 2017 4 2 Vivo Stockholder Agreement In connection with the August 2017 one no 4.5% 4.5% Pursuant to the Vivo Stockholder Agreement, Vivo will agree not August 2017 August 2017 one August 2017 third first August 2017 three August 2017 three no not, 33% August 2017 not 13 3 1934 In addition, the Company has agreed to register, via one August 2017 August 2017 no November 7, 2017, no December 22, 2017. may three 25% Stockholder Approval Pursuant to the August 2017 may August 2017 August 2017 August 2017 2018 August 2017 may, 90 2018 August 2017 not August 2017 first four August 2017 August 2017 August 2017 August 2017 no August 2017 August 2017 may not August 2017 August 2017 August 2017 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation and Principles of Consolidation The consolidated financial statements include the results of wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest with all significant intercompany accounts and transactions eliminated in consolidation. |
Unaudited Interim Financial Information [Policy Text Block] | Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (or U.S. GAAP) for interim financial information and Article 10 X not June 30, 2017, three six June 30, 2017 2016, six June 30, 2017 2016. December 31, 2016 not 10 10 December 31, 2016. |
Reverse Stock Split [Policy Text Block] | Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. not first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods reported. Actual results could differ from these estimates, and such differences may The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the six June 30, 2017 • ASU 2015 11, Inventory (Topic 330 • ASU 2016 06, Derivatives and Hedging (Topic 815 • ASU 2016 09, Compensation—Stock Compensation (Topic 718 None |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements Revenue Recognition May 2014, 2014 09, 606 , Revenue from Contracts with Customers 605, Revenue Recognition 2015 2016, first 2018. may first 2018. may not Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 first 2018. 2016 01 not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 Credit Losses of Financial Instruments June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 326 2016 13 first 2020 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 first 2018 Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 first 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not 2 not first 2018 When Changes to Share-based Payment Awards Must Be Accounted for as Modifications May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 not first 2018 |
Note 3 - Fair Value of Financ24
Note 3 - Fair Value of Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 5,078 $ — $ — $ 5,078 Certificates of deposit 5,371 — — 5,371 Total financial assets $ 10,449 $ — $ — $ 10,449 Financial Liabilities Compound embedded derivative liability $ — $ — $ 56,222 $ 56,222 Currency interest rate swap derivative liability — — 2,384 2,384 Total financial liabilities $ — $ — $ 58,606 $ 58,606 Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Compound embedded derivative liability $ — $ — $ 4,135 $ 4,135 Currency interest rate swap derivative liability — — 3,343 3,343 Total financial liabilities $ — $ — $ 7,478 $ 7,478 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2017 Balance at January 1 $ 4,135 Gain from change in fair value of derivative liabilities (in statements of operations) (32,210 ) Additions 93,675 Derecognition on extinguishment or conversion (9,378 ) Balance at June 30 $ 56,222 |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | June 30, 2017 May 11, 2017 December 31, 2016 Risk-free interest rate 1.29% - 1.93% 1.93% 0.55% - 1.31% Risk-adjusted yields 4.50% - 28.93% — 12.80% - 22.93% Stock-price volatility 45% - 80% 80% 45% Probability of change in control 5% 5% 5% Stock price $3.18 $4.95 $0.73 Credit spread 3.15% - 27.57% — 11.59% - 21.64% Estimated conversion dates 2017 - 2022 2017 - 2022 2017 - 2019 |
Derivative Instruments, Gain (Loss) [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, Type of Derivative Contract 2017 2016 2017 2016 Compound embedded derivative liabilities $ 35,814 $ 19,659 $ 36,315 $ 40,492 Currency interest rate swaps (39 ) 1,275 1,799 2,120 Total gain from change in fair value of derivative instruments $ 35,775 $ 20,934 $ 38,114 $ 42,612 |
Note 4 - Balance Sheet Compon25
Note 4 - Balance Sheet Components (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | June 30, December 31, Raw materials $ 2,937 $ 3,159 Work-in-process 1,379 1,848 Finished goods 1,413 1,206 Inventories $ 5,729 $ 6,213 |
Property, Plant and Equipment [Table Text Block] | June 30, December 31, 2016 Machinery and equipment $ 84,785 $ 82,688 Leasehold improvements 38,770 38,785 Computers and software 9,619 9,585 Buildings 4,630 4,699 Furniture and office equipment 2,324 2,333 Vehicles 133 164 Land 460 460 Construction in progress 367 2,216 141,088 140,930 Less: accumulated depreciation and amortization (91,785 ) (87,195 ) Property, plant and equipment, net $ 49,303 $ 53,735 |
Schedule of Other Assets, Noncurrent [Table Text Block] | June 30, December 31, Recoverable taxes from Brazilian government entities $ 15,443 $ 13,723 Cost-method investment 3,233 — Deposits on property and equipment, including taxes 909 291 Other 1,198 1,450 Total other assets $ 20,783 $ 15,464 |
Schedule of Accrued and Other Current Liabilities [Table Text Block] | June 30, December 31, Withholding tax related to conversion of related party notes $ 1,370 $ 1,370 Professional services 5,943 6,876 SMA relocation accrual 3,587 3,641 Accrued interest 4,133 4,847 Tax-related liabilities 2,741 2,610 Accrued vacation 2,274 2,034 Payroll and related expenses 3,512 4,310 Deferred rent, current portion 1,122 1,111 Contractual obligations to contract manufacturers 2,698 — Other 1,895 2,389 Total accrued and other current liabilities $ 29,275 $ 29,188 |
Note 5 - Debt and Mezzanine E26
Note 5 - Debt and Mezzanine Equity (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | June 30, 2017 December 31, 2016 Senior secured loan facility $ 27,999 $ 27,658 BNDES credit facility 577 1,172 FINEP credit facility 534 696 Guanfu credit facility 20,645 19,564 Total credit facilities 49,755 49,090 Convertible notes 54,471 78,981 Loans payable 14,592 26,527 Related party convertible notes 44,499 42,754 Related party loan payable 2,000 29,691 Total debt 165,317 227,043 Less: current portion (13,285 ) (59,155 ) Long-term debt, net of current portion $ 152,032 $ 167,888 Mezzanine equity Contingently redeemable common stock $ 5,000 $ 5,000 Convertible preferred stock $ 12,830 $ — |
Schedule of Long-term Debt Instruments [Table Text Block] | Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Related Party Loans Payable Credit Facility Total 2017 (remaining six months) $ 558 $ 4,123 $ 1,426 $ 2,487 $ 3,480 $ 12,074 2018 20,448 8,636 5,268 — 33,696 68,048 2019 34,913 68,097 2,665 — 2,577 108,252 2020 — — 2,559 — 2,500 5,059 2021 — — 2,451 — 27,396 29,847 Thereafter — — 4,057 — — 4,057 Total future minimum payments 55,919 80,856 18,426 2,487 69,649 227,337 Less: amount representing interest (1) (11,421 ) (26,385 ) (3,834 ) (487 ) (19,893 ) (62,020 ) Present value of minimum debt payments 44,498 54,471 14,592 2,000 49,756 165,317 Less: current portion (3,700 ) (1,517 ) (5,186 ) (2,000 ) (882 ) (13,285 ) Noncurrent portion of debt $ 40,798 $ 52,954 $ 9,406 $ — $ 48,874 $ 152,032 |
Note 6 - Commitments and Cont27
Note 6 - Commitments and Contingencies (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block] | Years ending December 31: Capital Operating Total Lease 2017 (remaining six months) $ 530 $ 3,406 $ 3,936 2018 106 6,889 6,995 2019 22 6,776 6,798 2020 — 7,006 7,006 2021 — 7,242 7,242 Thereafter — 10,958 10,958 Total future minimum payments $ 658 $ 42,277 $ 42,935 Less: amount representing interest (27 ) Present value of minimum lease payments 631 Less: current portion (598 ) Long-term portion $ 33 |
Note 7 - Joint Ventures and N28
Note 7 - Joint Ventures and Noncontrolling Interest (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Variable Interest Entities [Table Text Block] | (In thousands) June 30, 2017 December 31, 2016 Assets $ 32,541 $ 30,778 Liabilities 2,221 333 |
Noncontrolling Interest [Table Text Block] | 2017 2016 Balance at January 1 $ 937 $ — Acquisition of noncontrolling interest — 114 Balance at June 30 $ 937 $ 114 |
Note 9 - Goodwill and Intangi29
Note 9 - Goodwill and Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Intangible Assets and Goodwill [Table Text Block] | June 30, 2017 December 31, 2016 Useful Life in Years Gross Carrying Amount Accumulated Amortization Net Carrying Value Gross Carrying Amount Accumulated Amortization Net Carrying Value In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 |
Note 10 - Stock-based Compens30
Note 10 - Stock-based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] | Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2016 875,021 $ 55.20 Options granted 192,569 $ 6.94 — $ — Options exercised (133 ) $ 4.20 — $ — Options forfeited (70,182 ) $ 27.03 — $ — Outstanding - June 30, 2017 997,275 $ 47.87 7.01 $ 440 Vested and expected to vest after June 30, 2017 895,140 $ 51.99 6.76 $ 310 Exercisable at June 30, 2017 539,738 $ 76.14 5.36 $ — |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | RSUs Weighted- Weighted Average Outstanding - December 31, 2016 454,923 $ 17.48 Awarded 354,117 $ 6.74 — Vested (106,833 ) $ 22.33 — Forfeited (35,871 ) $ 13.76 — Outstanding - June 30, 2017 666,336 $ 11.20 1.64 Expected to vest after June 30, 2017 501,550 $ 11.56 1.45 |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 441 $ 485 $ 925 $ 976 Sales, general and administrative 597 1,304 1,759 2,864 Total stock-based compensation expense $ 1,038 $ 1,789 $ 2,684 $ 3,840 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Expected dividend yield — % — % — % — % Risk-free interest rate 1.82 % 1.4 % 1.82 % 1.4 % Expected term (in years) 5.38 6.16 5.38 6.16 Expected volatility 85.7 % 72.5 % 85.7 % 72.5 % |
Note 13 - Net Loss Per Share 31
Note 13 - Net Loss Per Share Attributable to Common Stockholders (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net income (loss) $ 620 $ (13,566 ) $ (36,751 ) $ (28,874 ) Less deemed dividend (capital distribution to related parties) (8,648 ) — (8,648 ) — Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) — (562 ) — Less cumulative dividends on Series A and Series B preferred stock (1,675 ) — (1,675 ) — Net loss attributable to Amyris, Inc. common stockholders, basic (10,265 ) (13,566 ) (47,636 ) (28,874 ) Interest on convertible debt — 1,591 — 3,501 Accretion of debt discount — 1,846 — 3,479 Loss (gain) from change in fair value of derivative instruments — (19,116 ) — (37,803 ) Net loss attributable to Amyris, Inc. common stockholders, diluted $ (10,265 ) $ (29,245 ) $ (47,636 ) $ (59,697 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 23,155,874 14,874,135 21,226,013 14,426,247 Basic loss per share $ (0.44 ) $ (0.91 ) $ (2.24 ) $ (2.00 ) Weighted-average shares of common stock outstanding 23,155,874 14,874,135 21,226,013 14,426,247 Effect of dilutive convertible promissory notes — 2,652,275 — 2,827,714 Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 23,155,874 17,526,410 21,226,013 17,253,961 Diluted loss per share $ (0.44 ) $ (1.67 ) $ (2.24 ) $ (3.46 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Period-end stock options to purchase common stock 997,275 948,603 997,275 948,603 Convertible promissory notes (1) 6,270,734 4,489,743 6,270,734 4,489,743 Period-end common stock warrants 16,871,700 193,429 16,871,700 193,429 Period-end restricted stock units 666,336 520,602 666,336 520,602 Total 24,806,045 6,152,377 24,806,045 6,152,377 |
Note 1 - The Company (Details T
Note 1 - The Company (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | ||
Aug. 31, 2017 | Jun. 30, 2017 | Dec. 31, 2016 | |
Working Capital | $ (21,800) | ||
Retained Earnings (Accumulated Deficit) | (1,171,189) | $ (1,134,438) | |
Cash, Cash Equivalents, and Short-term Investments | 6,600 | ||
Debt Instrument, Unamortized Discount | 26,000 | ||
Long-term Debt | 165,317 | 227,043 | |
Long-term Debt, Current Maturities, Including Due to Related Parties | 13,285 | $ 59,155 | |
Interest Payable | $ 11,200 | ||
Subsequent Event [Member] | DSM International B.V. and Vivo Capital, LLC. [Member] | |||
Proceeds from Issuance or Sale of Equity | $ 50,000 |
Note 2 - Summary of Significa33
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Jun. 05, 2016$ / sharesshares | Jun. 30, 2017$ / sharesshares | Dec. 31, 2016$ / sharesshares | Jun. 04, 2016shares |
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | |
Common Stock, Shares Authorized | shares | 250,000,000 | 250,000,000 | 500,000,000 | 500,000,000 |
Reverse Stock Split [Member] | ||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 |
Note 3 - Fair Value of Financ34
Note 3 - Fair Value of Financial Instruments (Details Textual) $ in Thousands, BRL in Millions | May 11, 2017 | Apr. 21, 2017USD ($)shares | Dec. 31, 2016USD ($) | Jun. 30, 2017USD ($) | Jun. 30, 2017BRL |
Loans Payable | $ 16,600 | ||||
Long-term Line of Credit | 49,800 | ||||
Convertible Debt | 99,000 | ||||
Loans Payable, Fair Value Disclosure | 13,400 | ||||
Lines of Credit, Fair Value Disclosure | 32,600 | ||||
Convertible Debt, Fair Value Disclosures | 95,800 | ||||
Fair Value Assumptions, Risk Free Interest Rate | 1.93% | ||||
Fair Value Assumptions, Expected Volatility Rate | 80.00% | 45.00% | |||
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member] | |||||
Derivative, Notional Amount | $ 6,700 | BRL 22 | |||
Derivative, Fixed Interest Rate | 3.94% | 3.94% | |||
SweeGen Common Stock [Member] | |||||
Equity Method Investment, Aggregate Cost | $ 3,200 | ||||
Fair Value Inputs, Discount Rate | 40.00% | ||||
Fair Value Assumptions, Risk Free Interest Rate | 0.92% | ||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||
Fair Value Assumptions, Expected Volatility Rate | 45.00% | ||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member] | |||||
Shares Received in Satisfaction of Payment Obligation | shares | 850,115 | ||||
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 4,135 | $ 56,222 | |||
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 4,100 | $ 56,200 |
Note 3 - Fair Value of Financ35
Note 3 - Fair Value of Financial Instruments - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Total financial assets | $ 10,449 | $ 2,922 |
Compound embedded derivative liability | 56,222 | 4,135 |
Currency interest rate swap derivative liability | 2,384 | 3,343 |
Total financial liabilities | 58,606 | 7,478 |
Money market funds | 5,078 | 1,549 |
Certificates of deposit | 5,371 | 1,373 |
Fair Value, Inputs, Level 1 [Member] | ||
Total financial assets | 10,449 | 2,922 |
Money market funds | 5,078 | 1,549 |
Certificates of deposit | 5,371 | 1,373 |
Fair Value, Inputs, Level 3 [Member] | ||
Compound embedded derivative liability | 56,222 | 4,135 |
Currency interest rate swap derivative liability | 2,384 | 3,343 |
Total financial liabilities | $ 58,606 | $ 7,478 |
Note 3 - Fair Value of Financ36
Note 3 - Fair Value of Financial Instruments - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Liability, Compound Embedded Derivatives [Member] $ in Thousands | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Balance, compound embedded derivative liabilities | $ 4,135 |
Gain from change in fair value of derivative liabilities (in statements of operations) | (32,210) |
Additions | 93,675 |
Derecognition on extinguishment or conversion | (9,378) |
Balance, compound embedded derivative liabilities | $ 56,222 |
Note 3 - Fair Value of Financ37
Note 3 - Fair Value of Financial Instruments - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares | May 11, 2017 | Jun. 30, 2017 | Dec. 31, 2016 |
Fair Value Assumptions, Risk Free Interest Rate | 1.93% | ||
Fair Value Assumptions, Expected Volatility Rate | 80.00% | 45.00% | |
Probability of change in control | 5.00% | 5.00% | 5.00% |
Share Price | $ 4.95 | $ 3.18 | $ 0.73 |
Estimated conversion dates | |||
Minimum [Member] | |||
Fair Value Assumptions, Risk Free Interest Rate | 1.29% | 0.55% | |
Fair Value Assumptions, Expected Dividend Rate | 4.50% | 12.80% | |
Fair Value Assumptions, Expected Volatility Rate | 45.00% | ||
Credit spread | 3.15% | 11.59% | |
Estimated conversion dates | 2,017 | 2,017 | 2,017 |
Maximum [Member] | |||
Fair Value Assumptions, Risk Free Interest Rate | 1.93% | 1.31% | |
Fair Value Assumptions, Expected Dividend Rate | 28.93% | 22.93% | |
Fair Value Assumptions, Expected Volatility Rate | 80.00% | ||
Credit spread | 27.57% | 21.64% | |
Estimated conversion dates | 2,022 | 2,022 | 2,019 |
Note 3 - Fair Value of Financ38
Note 3 - Fair Value of Financial Instruments - Derivative Instruments Classification (Details) - Gain (Loss) From Change in Fair Value of Derivative Instruments [Member] - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
(Loss) gain from change in fair value of derivative instruments | $ 35,775 | $ 20,934 | $ 38,114 | $ 42,612 |
Embedded Derivative Financial Instruments [Member] | ||||
(Loss) gain from change in fair value of derivative instruments | 35,814 | 19,659 | 36,315 | 40,492 |
Currency Interest Rate Swap [Member] | ||||
(Loss) gain from change in fair value of derivative instruments | $ (39) | $ 1,275 | $ 1,799 | $ 2,120 |
Note 4 - Balance Sheet Compon39
Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 | |
Property, Plant and Equipment, Gross | $ 141,088 | $ 141,088 | $ 140,930 | ||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 91,785 | 91,785 | 87,195 | ||
Depreciation, Depletion and Amortization | 5,550 | $ 5,720 | |||
Property, Plant and Equipment, Including Capital Leases [Member] | |||||
Depreciation, Depletion and Amortization | 2,700 | $ 2,800 | 5,400 | $ 5,700 | |
Capital Lease Obligations [Member] | |||||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 300 | 300 | 600 | ||
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member] | |||||
Property, Plant and Equipment, Gross | $ 3,400 | $ 3,400 | $ 3,100 |
Note 4 - Balance Sheet Compon40
Note 4 - Balance Sheet Components - Inventory, Current (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Raw materials | $ 2,937 | $ 3,159 |
Work-in-process | 1,379 | 1,848 |
Finished goods | 1,413 | 1,206 |
Inventories | $ 5,729 | $ 6,213 |
Note 4 - Balance Sheet Compon41
Note 4 - Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Property, plant and equipment | $ 141,088 | $ 140,930 |
Less: accumulated depreciation and amortization | (91,785) | (87,195) |
Property, plant and equipment, net | 49,303 | 53,735 |
Machinery and Equipment [Member] | ||
Property, plant and equipment | 84,785 | 82,688 |
Leasehold Improvements [Member] | ||
Property, plant and equipment | 38,770 | 38,785 |
Computer Equipment and Software [Member] | ||
Property, plant and equipment | 9,619 | 9,585 |
Building [Member] | ||
Property, plant and equipment | 4,630 | 4,699 |
Furniture and Fixtures [Member] | ||
Property, plant and equipment | 2,324 | 2,333 |
Vehicles [Member] | ||
Property, plant and equipment | 133 | 164 |
Land [Member] | ||
Property, plant and equipment | 460 | 460 |
Construction in Progress [Member] | ||
Property, plant and equipment | $ 367 | $ 2,216 |
Note 4 - Balance Sheet Compon42
Note 4 - Balance Sheet Components - Other Assets, Noncurrent (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Recoverable taxes from Brazilian government entities | $ 15,443 | $ 13,723 |
Cost-method investment | 3,233 | |
Deposits on property and equipment, including taxes | 909 | 291 |
Other | 1,198 | 1,450 |
Total other assets | $ 20,783 | $ 15,464 |
Note 4 - Balance Sheet Compon43
Note 4 - Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Withholding tax related to conversion of related party notes | $ 1,370 | $ 1,370 |
Professional services | 5,943 | 6,876 |
SMA relocation accrual | 3,587 | 3,641 |
Accrued interest | 4,133 | 4,847 |
Tax-related liabilities | 2,741 | 2,610 |
Accrued vacation | 2,274 | 2,034 |
Payroll and related expenses | 3,512 | 4,310 |
Deferred rent, current portion | 1,122 | 1,111 |
Contractual obligations to contract manufacturers | 2,698 | |
Other | 1,895 | 2,389 |
Total accrued and other current liabilities | $ 29,275 | $ 29,188 |
Note 5 - Debt and Mezzanine E44
Note 5 - Debt and Mezzanine Equity (Details Textual) $ / shares in Units, BRL in Millions | Jun. 30, 2017USD ($)$ / sharesshares | Jun. 06, 2017$ / shares | May 31, 2017USD ($)$ / sharesshares | May 11, 2017USD ($)$ / sharesshares | May 08, 2017USD ($)$ / sharesshares | May 02, 2017USD ($)shares | Apr. 17, 2017USD ($) | Jan. 11, 2017USD ($) | Dec. 28, 2016USD ($) | Dec. 01, 2016USD ($) | Oct. 26, 2016USD ($) | Oct. 13, 2016USD ($) | Jun. 05, 2016 | May 10, 2016USD ($)$ / sharesshares | Feb. 15, 2016USD ($)$ / sharesshares | Feb. 15, 2016USD ($)$ / sharesshares | Oct. 20, 2015USD ($) | Oct. 14, 2015USD ($)$ / sharesshares | Jul. 29, 2015USD ($)$ / sharesshares | May 31, 2017USD ($)$ / sharesshares | Jan. 31, 2017USD ($) | Dec. 31, 2016USD ($)$ / shares | Oct. 31, 2016USD ($) | Mar. 31, 2016USD ($) | Mar. 31, 2016EUR (€) | Oct. 31, 2015USD ($) | Jul. 31, 2015USD ($)shares | May 31, 2014USD ($)$ / shares | Jan. 31, 2014USD ($) | Oct. 31, 2013USD ($)$ / shares | Aug. 31, 2013USD ($) | Jul. 31, 2012USD ($) | Jun. 30, 2017USD ($)$ / sharesshares | Mar. 31, 2017USD ($) | Jun. 30, 2016USD ($) | Jun. 30, 2017USD ($)$ / sharesshares | Jun. 30, 2017BRLshares | Jun. 30, 2016USD ($) | Dec. 31, 2015USD ($) | Nov. 30, 2015USD ($) | Jun. 30, 2017BRLshares | May 01, 2017 | Apr. 13, 2017USD ($)shares | Feb. 28, 2017 | Feb. 27, 2017 | Dec. 31, 2016BRL | Oct. 27, 2016USD ($) | Oct. 21, 2016USD ($) | Jun. 24, 2016USD ($) | May 31, 2016USD ($) | Feb. 28, 2016shares | Feb. 12, 2016USD ($)shares | Mar. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Oct. 04, 2013 | Feb. 28, 2012USD ($)$ / shares |
Share Price | $ / shares | $ 3.18 | $ 4.95 | $ 0.73 | $ 3.18 | $ 3.18 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 35,775,000 | $ 20,934,000 | $ 38,114,000 | $ 42,612,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | $ 8,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquistion Cost for Equipment Under Guarantee | $ 1,800,000 | 1,800,000 | 1,800,000 | BRL 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 49,800,000 | 49,800,000 | 49,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | 12,455,000 | 9,950,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (1,900,000) | $ 4,200,000 | (3,624,000) | (433,000) | (3,528,000) | (649,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | 99,000,000 | 99,000,000 | 99,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 26,000,000 | 26,000,000 | 26,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 165,317,000 | $ 227,043,000 | $ 165,317,000 | $ 165,317,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 40,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ 50,661,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Embedded Derivative Financial Instruments [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 9,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock Converted Into Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | shares | 18,840 | 18,840 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Due to Related Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 33,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | shares | 22,140 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Stated Value | $ / shares | $ 1,000 | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ / shares | $ 17.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | 17.38% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Anniversary Payment | $ / shares | $ 1,738 | $ 1,738 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Preferred Stock, Beneficial Conversion Feature, Proceeds Allocated to Preferred Stock | $ 600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Preferred Stock, Proceeds Allocated to Preferred Stock | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | shares | 70,904 | 70,904 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ 30,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 34,700,000 | $ 34,700,000 | $ 34,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | Selling, General and Administrative Expenses [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issuance Costs Recognized | $ 800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Stated Value | $ / shares | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Conversion Rate | $ / shares | $ 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.15 | $ 0.15 | $ 0.15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | 13.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gates Foundation Purchase Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 292,398 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 17.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compound Annual Return | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temporary Equity, Carrying Amount, Attributable to Parent | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 2017 Offering Closing [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | 50,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 2017 Offering Closing [Member] | Series A Preferred Stock and Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | 22,140,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 2017 Offering Closing [Member] | Series B Preferred Stock and Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 30,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 2017 Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 14,768,380 | 14,768,380 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 39,500,000 | $ 39,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 2017 Warrants, Warrant 1 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Available for Conversion, Percentage | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 7,384,190 | 7,384,190 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 7.80 | $ 7.80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 2017 Warrants, Warrant 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 7,384,190 | 7,384,190 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 9.30 | $ 9.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dilution Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock Effective Conversion Price | $ / shares | $ 6.30 | $ 6.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 4,400,000 | $ 4,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.0015 | $ 0.0015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
JVCO Joint Venture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 9.99% | 9.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 4.99% | 4.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse Stock Split [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | JVCO Joint Venture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage by Counterparty | 75.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foris Ventures, LLC [Member] | Due to Related Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 27,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foris Ventures, LLC [Member] | Series B Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,728.589 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares | 4,877,386 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Naxyris S.A. [Member] | Due to Related Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Naxyris S.A. [Member] | Series B Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,333.216 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares | 370,404 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foris and Naxyris [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | shares | 1,394,706 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foris and Naxyris [Member] | Series C Preferred Stock [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | shares | 20,921 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt | 1.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 54,471,000 | $ 78,981,000 | $ 54,471,000 | $ 54,471,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (9,400,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 44,499,000 | 42,754,000 | 44,499,000 | 44,499,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | The Second Tranche [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Exchanged and Cancelled | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Promissory Notes, 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 2,000,000 | 2,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Promissory Notes, 2016 [Member] | Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | $ 2,000,000 | $ 18,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | 19,048 | 171,429 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.15 | $ 0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foris Ventures, LLC [Member] | Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 152,381 | 152,381 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Naxyris S.A. [Member] | Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | 19,048 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biolding Investment SA [Member] | Private Placement February 2016 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | 19,048 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
DSM International B.V. [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ownership Percentage, Designated Director Threshold | 4.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserved Second Tranche Securities | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche Closing, Anniversary Payment | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 3,968,116 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
DSM International B.V. [Member] | Series B Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
DSM International B.V. [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserved Second Tranche Securities | $ 30,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
DSM International B.V. [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserved Second Tranche Securities | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foris and Naxyris [Member] | Series C Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINEP Credit Facility [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 500,000 | 700,000 | $ 500,000 | $ 500,000 | BRL 1.8 | BRL 2.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Guanfu Credit Agreement [Member] | Guanfu Holding Co., Ltd [Member] | Unsecured Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage | 100.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Percentage | 90.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Number of Trading Days | 90 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 106.023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Offering | $ 75,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 72,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Denominator [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Reverse Stock Split [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Ratio | 17.8073 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 56.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amount of Convertible Debt Purchased by Affiliated Entities | 24,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 18,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 6.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Shares | shares | 48.3395 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 20.69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion | 92.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Trading Days Notes Become Convertible | 10 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Additional Principal Amount Issued During Period | $ 19,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage | 19.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 54,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 6.5% [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 18,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 3% [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 14,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 9,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The April 2017 Convertible Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 6,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The April 2017 Convertible Notes [Member] | Convertible Debt [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The April 2017 Convertible Notes, Initial Closing [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Amended Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Securities, Monthly Installment Discount | 20.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Securities, Price Floor Payment Discount Rate | 70.00% | 80.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Amended Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Monthly Installments, Percent of Installment Amount | 118.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Events of Default, Percentage of Amount can be Redeemed by Holders | 118.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Events of Fundamental Transaction, Percentage of Amount can be Redeemed by Holders | 118.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 28.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | shares | 3,792,779 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Minimum | shares | 15.75 | 15.75 | 15.75 | 15.75 | 218,817 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares | $ 15 | $ 15 | $ 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 19,100,000 | 9,900,000 | $ 19,100,000 | $ 19,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
The 3 Million Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | 3,000,000 | 3,000,000 | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Purchase Agreement [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 105,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Initial Closing [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured R&D Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Including Interest | $ 2,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 1,300,000 | € 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Replacement Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 3,700,000 | 3,700,000 | $ 3,700,000 | $ 3,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 46.20 | $ 46.20 | $ 46.20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | 1.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 73,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement Convertible Notes, Period | 2 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek Bridge Loan [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (19,900,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.44 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Discount Percentage to Determine Conversion Price | 15.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price | 60 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plant Manufacturing Production, Product Sales, Percentage | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period | 180 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 44,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 7,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 51,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 9,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 35,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Cancellation of Debt, Amount | $ 9,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 34,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I and Tranche II Notes [Member] | Related Party Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.425 | $ 7.425 | $ 7.425 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 22,100,000 | 21,800,000 | $ 22,100,000 | $ 22,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I Notes [Member] | Temasek Funding Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,125,755 | 1,125,755 | 164,169 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2016 Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Foris Ventures, LLC [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 6,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Ginkgo Bioworks, Inc. [Member] | Convertible Subordinated Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 8,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Salisbury Note [Member] | Salisbury Partners, LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Equal Monthly Installments, Amount | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Payments Required in Four Monthly Installments | $ 400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche II Notes [Member] | Temasek Funding Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 164,169 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Loan and Security Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 30,960,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Long-term Lines of Credit | 15,960,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Financing Costs | $ 1,450,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stegodon [Member] | Loan and Security Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Issuance Costs, Line of Credit Arrangements, Net | 600,000 | 600,000 | 600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrumebt, Requirement, Maximum Monthly Repayment, Using Proceeds from Collaboration Agreement | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Monies Agreed to Apply Toward Repayment of Outstanding Loans, Maximum | $ 3,000,000 | $ 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 27,800,000 | 27,800,000 | 27,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa and Banco Pine Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Period of Interest Only QuarterlyPayments | 2 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 10,000,000 | $ 11,100,000 | 10,000,000 | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Certain Farnesene Production Assets Pledged as Collateral for Loans | 15,700,000 | 15,700,000 | 15,700,000 | BRL 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | 20,600,000 | BRL 68 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,700,000 | $ 15,700,000 | $ 15,700,000 | BRL 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant 1 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Numerator One | 30.60% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Denominator One | 69.40% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Numerator Two | 13.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Denominator Two | 86.70% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 133,334 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares | 58,690 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | The 2013 Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 846,683 | 66,667 | 846,683 | 846,683 | 846,683 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | shares | 1,289,924 | 1,289,924 | 1,289,924 | 1,289,924 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.15 | $ 0.01 | $ 0.15 | $ 0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | Temasek Warrant Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares | 58,690 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 70,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Total Funding Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,261,612 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Total R&D Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,333,334 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Temasek Warrant 1 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 978,525 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Temasek Warrant 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 133,334 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Tranche I and Tranche II Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 15,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Rule 144A Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total and Temasek [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 34.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Expense, Debt | $ 39,200,000 |
Note 5 - Debt and Mezzanine E45
Note 5 - Debt and Mezzanine Equity - Debt Components (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Debt | $ 165,317 | $ 227,043 |
Less: current portion | (13,285) | (59,155) |
Long-term debt, net of current portion | 152,032 | 167,888 |
Contingently Redeemable Common Stock [Member] | ||
Mezzanine Equity | 5,000 | 5,000 |
Convertible Preferred Stock [Member] | ||
Mezzanine Equity | 12,830 | |
Stegodon [Member] | ||
Debt | 27,999 | 27,658 |
BNDES Credit Facility [Member] | ||
Debt | 577 | 1,172 |
FINEP Credit Facility [Member] | ||
Debt | 534 | 696 |
Guanfu Credit Facility [Member] | ||
Debt | 20,645 | 19,564 |
Credit Facility [Member] | ||
Debt | 49,755 | 49,090 |
Long-term debt, net of current portion | 48,874 | |
Convertible Debt [Member] | ||
Debt | 54,471 | 78,981 |
Long-term debt, net of current portion | 52,954 | |
Loans Payable [Member] | ||
Debt | 14,592 | 26,527 |
Long-term debt, net of current portion | 9,406 | |
Related Party Convertible Notes [Member] | ||
Debt | 44,499 | 42,754 |
Long-term debt, net of current portion | 40,798 | |
Related Party Loan Payable [Member] | ||
Debt | 2,000 | $ 29,691 |
Long-term debt, net of current portion |
Note 5 - Debt and Mezzanine E46
Note 5 - Debt and Mezzanine Equity - Long-term Debt Instruments (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 | |
2017 (remaining six months) | $ 12,074 | ||
2,018 | 68,048 | ||
2,019 | 108,252 | ||
2,020 | 5,059 | ||
2,021 | 29,847 | ||
Thereafter | 4,057 | ||
Total future minimum payments | 227,337 | ||
Less: amount representing interest(1) | [1] | (62,020) | |
Present value of minimum debt payments | 165,317 | ||
Less: current portion | (13,285) | ||
Long-term debt, net of current portion | 152,032 | $ 167,888 | |
Related Party Convertible Notes [Member] | |||
2017 (remaining six months) | 558 | ||
2,018 | 20,448 | ||
2,019 | 34,913 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments | 55,919 | ||
Less: amount representing interest(1) | [1] | (11,421) | |
Present value of minimum debt payments | 44,498 | ||
Less: current portion | (3,700) | ||
Long-term debt, net of current portion | 40,798 | ||
Convertible Debt [Member] | |||
2017 (remaining six months) | 4,123 | ||
2,018 | 8,636 | ||
2,019 | 68,097 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments | 80,856 | ||
Less: amount representing interest(1) | [1] | (26,385) | |
Present value of minimum debt payments | 54,471 | ||
Less: current portion | (1,517) | ||
Long-term debt, net of current portion | 52,954 | ||
Loans Payable [Member] | |||
2017 (remaining six months) | 1,426 | ||
2,018 | 5,268 | ||
2,019 | 2,665 | ||
2,020 | 2,559 | ||
2,021 | 2,451 | ||
Thereafter | 4,057 | ||
Total future minimum payments | 18,426 | ||
Less: amount representing interest(1) | [1] | (3,834) | |
Present value of minimum debt payments | 14,592 | ||
Less: current portion | (5,186) | ||
Long-term debt, net of current portion | 9,406 | ||
Related Party Loan Payable [Member] | |||
2017 (remaining six months) | 2,487 | ||
2,018 | |||
2,019 | |||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments | 2,487 | ||
Less: amount representing interest(1) | [1] | (487) | |
Present value of minimum debt payments | 2,000 | ||
Less: current portion | (2,000) | ||
Long-term debt, net of current portion | |||
Credit Facility [Member] | |||
2017 (remaining six months) | 3,480 | ||
2,018 | 33,696 | ||
2,019 | 2,577 | ||
2,020 | 2,500 | ||
2,021 | 27,396 | ||
Thereafter | |||
Total future minimum payments | 69,649 | ||
Less: amount representing interest(1) | [1] | (19,893) | |
Present value of minimum debt payments | 49,756 | ||
Less: current portion | (882) | ||
Long-term debt, net of current portion | $ 48,874 | ||
[1] | includes debt discount & issuance cost associated with related party & non-related party debt which will accrete to interest expense under the effective interest method over the term of the debt. |
Note 6 - Commitments and Cont47
Note 6 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 | |
Purchase Obligation | $ 900 | $ 900 | $ 800 | ||
Contractual Obligation | 600 | 600 | 600 | ||
Operating Leases, Rent Expense | 1,400 | $ 1,400 | 2,800 | $ 2,700 | |
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net | 0 | 0 | $ 0 | ||
Manufacturing Agreement, Aprinnova JV [Member] | |||||
Contractual Obligation | $ 10,000 | $ 10,000 |
Note 6 - Commitments and Cont48
Note 6 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Capital leases 2017 (remaining nine months) | $ 530 | |
Operating leases 2017 (remaining nine months) | 3,406 | |
Total lease obligations 2017 (remaining nine months) | 3,936 | |
Capital leases 2018 | 106 | |
Operating leases 2018 | 6,889 | |
Total lease obligations 2018 | 6,995 | |
Capital leases 2019 | 22 | |
Operating leases 2019 | 6,776 | |
Total lease obligations 2019 | 6,798 | |
Capital leases 2020 | 0 | |
Operating leases 2020 | 7,006 | |
Total lease obligations 2020 | 7,006 | |
Capital leases 2021 | 0 | |
Operating leases 2021 | 7,242 | |
Total lease obligations 2021 | 7,242 | |
Capital leases thereafter | 0 | |
Operating leases thereafter | 10,958 | |
Total lease obligations thereafter | 10,958 | |
Total future minimum capital lease payments | 658 | |
Total future minimum operating lease payments | 42,277 | |
Total future minimum lease payments | 42,935 | |
Less: amount representing interest | (27) | |
Present value of minimum lease payments | 631 | |
Less: current portion | (598) | $ (922) |
Capital lease obligation, net of current portion | $ 33 | $ 334 |
Note 7 - Joint Ventures and N49
Note 7 - Joint Ventures and Noncontrolling Interest (Details Textual) | Jun. 30, 2017 |
Aprinnova JV [Member] | |
Noncontrolling Interest, Ownership Percentage by Parent | 50.00% |
Note 7 - Joint Ventures and N50
Note 7 - Joint Ventures and Noncontrolling Interest - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Assets | $ 32,541 | $ 30,778 |
Liabilities | $ 2,221 | $ 333 |
Note 7 - Joint Ventures and N51
Note 7 - Joint Ventures and Noncontrolling Interest - Noncontrolling Interest (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Balance, noncontrolling interest | $ 937 | |
Balance, noncontrolling interest | 937 | |
Noncontrolling Interest [Member] | ||
Balance, noncontrolling interest | 937 | $ 0 |
Acquisition of noncontrolling interest | 0 | 114 |
Balance, noncontrolling interest | $ 937 | $ 114 |
Note 8 - Significant Agreemen52
Note 8 - Significant Agreements (Details Textual) | Jan. 15, 2018USD ($) | May 08, 2017USD ($) | Apr. 21, 2017shares | Jan. 15, 2017USD ($) | Nov. 30, 2016USD ($) | Sep. 30, 2016 | Jul. 25, 2016USD ($) | Mar. 08, 2016USD ($) | Apr. 30, 2014USD ($) | Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Apr. 30, 2016 | Sep. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Mar. 31, 2014USD ($) | Mar. 31, 2013USD ($) | Jun. 30, 2017USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Mar. 31, 2017USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Apr. 30, 2017USD ($) |
At the Market Offering [Member] | |||||||||||||||||||||||
Commission Rate | 3.00% | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 0 | ||||||||||||||||||||||
Common Stock, Value, Subscriptions | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | 50,000,000 | |||||||||||||||||||
Ginkgo Collaboration Note [Member] | Secured Promissory Note [Member] | |||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | ||||||||||||||||||||||
Technology Investment Agreement with DARPA [Member] | |||||||||||||||||||||||
Maximum DARPA Funding to be Received if all Milestones are Achieved | $ 35,000,000 | ||||||||||||||||||||||
Collaboration Agreement Period | 4 years | ||||||||||||||||||||||
Collective Obligation Due | $ 15,500,000 | ||||||||||||||||||||||
Revenue from Related Parties | 4,700,000 | $ 2,300,000 | 5,700,000 | $ 3,500,000 | |||||||||||||||||||
Firmenich [Member] | |||||||||||||||||||||||
Additional Grants and Collaboration Funding | 5,000,000 | ||||||||||||||||||||||
Firmenich [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 2,100,000 | 1,300,000 | 3,200,000 | 4,300,000 | |||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 10 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 3 years | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum | 1 year | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year One | $ 10,000,000 | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year Three | $ 10,000,000 | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year Two | $ 10,000,000 | ||||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Master Collaboration Agreement [Member] | |||||||||||||||||||||||
Sales Margin Company Percentage Split | 30.00% | ||||||||||||||||||||||
Sales Margin Collaborator Percentage Split | 70.00% | ||||||||||||||||||||||
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin | $ 15,000,000 | ||||||||||||||||||||||
Sales Margin Company Percentage Split Following Return Requirements | 50.00% | ||||||||||||||||||||||
Success Bonus | $ 2,500,000 | ||||||||||||||||||||||
Revenue from Related Parties | 900,000 | 2,600,000 | 2,100,000 | 4,600,000 | |||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Amended Collaboration Agreement [Member] | |||||||||||||||||||||||
Royalty Rate, Percent of Net Revenue | 10.00% | ||||||||||||||||||||||
Kuraray [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 2 years | ||||||||||||||||||||||
Revenue from Related Parties | 100,000 | 400,000 | 300,000 | 800,000 | |||||||||||||||||||
Proceeds from Collaborators | $ 500,000 | $ 2,000,000 | $ 2,000,000 | $ 4,000,000 | |||||||||||||||||||
Deferred Revenue | $ 1,000,000 | ||||||||||||||||||||||
Collaborative Agreement Number Of Installments | 2 | 2 | |||||||||||||||||||||
Kuraray [Member] | Collaborative Arrangement [Member] | Scenario, Forecast [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | $ 500,000 | ||||||||||||||||||||||
Kuraray [Member] | Product Sales [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 1,900,000 | 200,000 | 3,600,000 | 200,000 | |||||||||||||||||||
Nenter & Co., Inc. [Member] | |||||||||||||||||||||||
Value-share Arrangement, Amount Receiable, Remainder of Fiscal Year | 2,400,000 | 2,400,000 | 2,400,000 | ||||||||||||||||||||
Loss on Contract Termination | $ 2,500,000 | ||||||||||||||||||||||
Nenter & Co., Inc. [Member] | Supply Agreements [Member] | |||||||||||||||||||||||
Supply Agreement, Renewable Terms | 5 years | ||||||||||||||||||||||
Revenue from Related Parties | 6,600,000 | 0 | 8,900,000 | 30,000 | |||||||||||||||||||
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Semi Annual Installments, Amount | $ 3,000,000 | ||||||||||||||||||||||
Revenue from Related Parties | 1,500,000 | $ 0 | 3,000,000 | $ 0 | |||||||||||||||||||
Proceeds from Collaborators | 12,000,000 | ||||||||||||||||||||||
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | Deferred Revenue [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | 3,000,000 | $ 3,000,000 | $ 3,000,000 | ||||||||||||||||||||
Ginkgo Bioworks [Member] | |||||||||||||||||||||||
Royalty Percentage | 10.00% | 10.00% | 10.00% | ||||||||||||||||||||
Collaboration Agreement Period | 3 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 1 year | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum | 90 days | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term Due to Lack of Commitment | 30 days | ||||||||||||||||||||||
Revenue from Related Parties | 0 | ||||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue, Term Exercisable from Date of Issuance | 1 year | ||||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue | shares | 333,334 | 333,334 | 333,334 | ||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue, Exercise Price Per Share | $ / shares | $ 7.50 | $ 7.50 | $ 7.50 | ||||||||||||||||||||
Proceeds from Collaborators | $ 15,000,000 | $ 20,000,000 | 0 | $ 5,000,000 | |||||||||||||||||||
Collaborative Agreement Number Of Installments | 2 | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | Ginkgo Collaboration Agreement [Member] | |||||||||||||||||||||||
Accounts Payable | $ 1,500,000 | 1,500,000 | 1,500,000 | ||||||||||||||||||||
Revenue from Related Parties | 0 | $ 0 | 0 | $ 0 | |||||||||||||||||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | |||||||||||||||||||||||
Accounts Receivable, Gross | $ 10,000,000 | ||||||||||||||||||||||
Revenue from Related Parties | $ 10,000,000 | $ 2,700,000 | $ 0 | $ 2,700,000 | $ 0 | ||||||||||||||||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member] | |||||||||||||||||||||||
Shares Received in Satisfaction of Payment Obligation | shares | 850,115 |
Note 9 - Goodwill and Intangi53
Note 9 - Goodwill and Intangible Assets - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017 | Dec. 31, 2016 | |
Goodwill, carrying amount | $ 560 | $ 560 |
Goodwill, net carrying value | 560 | 560 |
Intangible assets impairment and accumulated amortization | (9,332) | (9,332) |
Goodwill and intangible assets, net | 560 | 560 |
Goodwill and intangible assets, gross | 9,892 | 9,892 |
Acquired Licenses and Permits [Member] | ||
Accumulated amortization of intangible assets | (772) | (772) |
In-process research and development, carrying amount | $ 772 | 772 |
Acquired licenses and permits, useful life (Year) | 2 years | |
In Process Research and Development, Indefinite [Member] | ||
In-process research and development, carrying amount | $ 8,560 | 8,560 |
In-process research and development | (8,560) | (8,560) |
In-process research and development, net carrying value |
Note 10 - Stock-based Compens54
Note 10 - Stock-based Compensation (Details Textual) $ in Millions | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Restricted Stock Units (RSUs) [Member] | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 8.5 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 328 days |
Employee Stock Option [Member] | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 8.5 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 328 days |
Note 10 - Stock-based Compens55
Note 10 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) $ / shares in Units, $ in Thousands | 6 Months Ended |
Jun. 30, 2017USD ($)$ / sharesshares | |
Outstanding (in shares) | shares | 875,021 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 55.20 |
Options granted (in shares) | shares | 192,569 |
Options granted, weighted average exercise price (in dollars per share) | $ / shares | $ 6.94 |
Options exercised (in shares) | shares | (133) |
Options exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 4.20 |
Options forfeited (in shares) | shares | (70,182) |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 47.87 |
Outstanding, weighted average remaining contractual life (Year) | 7 years 3 days |
Outstanding, aggregate intrinsic value | $ | $ 440 |
Vested and expected to vest after June 30, 2017 (in shares) | shares | 895,140 |
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share) | $ / shares | $ 51.99 |
Options forfeited, weighted average exercise price (in dollars per share) | $ / shares | $ 27.03 |
Outstanding (in shares) | shares | 997,275 |
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 6 years 277 days |
Vested and expected to vest after December 31, 2016, aggregate intrinsic value | $ | $ 310 |
Exercisable at June 30, 2017 (in shares) | shares | 539,738 |
Exercisable at December 31, 2016, weighted average exercise price (in dollars per share) | $ / shares | $ 76.14 |
Exercisable at December 31, 2016, weighted average remaining contractual life (Year) | 5 years 131 days |
Exercisable at December 31, 2016, aggregate intrinsic value | $ |
Note 10 - Stock-based Compens56
Note 10 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017 | Dec. 31, 2016 | |
Outstanding, RSUs (in shares) | 454,923 | |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 17.48 | |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 11.20 | $ 17.48 |
Outstanding, weighted average remaining contractual life (Year) | 1 year 233 days | |
Awarded (in shares) | 354,117 | |
Awarded (in dollars per share) | $ 6.74 | |
Vested (in shares) | (106,833) | |
Vested (in dollars per share) | $ 22.33 | |
Forfeited (in shares) | (35,871) | |
Forfeited (in dollars per share) | $ 13.76 | |
Expected to vest after June 30, 2017 (in shares) | 501,550 | |
Expected to vest after December 31, 2016, weighted average grant-date fair value (in dollars per share) | $ 11.56 | |
Expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 1 year 164 days | |
Outstanding, RSUs (in shares) | 666,336 | 454,923 |
Note 10 - Stock-based Compens57
Note 10 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Allocated share-based compensation expense | $ 1,038 | $ 1,789 | $ 2,684 | $ 3,840 |
Research and Development Expense [Member] | ||||
Allocated share-based compensation expense | 441 | 485 | 925 | 976 |
Selling, General and Administrative Expenses [Member] | ||||
Allocated share-based compensation expense | $ 597 | $ 1,304 | $ 1,759 | $ 2,864 |
Note 10 - Stock-based Compens58
Note 10 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member] | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Expected dividend yield | ||||
Risk-free interest rate | 1.82% | 1.40% | 1.82% | 1.40% |
Expected term (Year) | 5 years 138 days | 6 years 58 days | 5 years 138 days | 6 years 58 days |
Expected volatility | 85.70% | 72.50% | 85.70% | 72.50% |
Note 11 - Related Party Trans59
Note 11 - Related Party Transactions (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 | Jul. 31, 2015 | |
Convertible Debt | $ 99,000,000 | $ 99,000,000 | ||||
Debt Instrument, Unamortized Discount | 26,000,000 | 26,000,000 | ||||
Novvi LLC [Member] | ||||||
Equity Method Investments | 60,000 | 60,000 | ||||
DSM International B.V. [Member] | ||||||
Revenue from Related Parties | 100,000 | $ 100,000 | 100,000 | $ 100,000 | ||
Accounts Receivable, Related Parties | 600,000 | $ 600,000 | $ 800,000 | |||
Total [Member] | ||||||
Convertible Debt | $ 5,000,000 | |||||
Total [Member] | Pilot Plant Agreements [Member] | ||||||
Related Party Agreement Term | 5 years | |||||
Due to Related Parties | 1,400,000 | $ 1,400,000 | 1,800,000 | |||
Related Party Convertible Notes [Member] | ||||||
Convertible Debt | 46,300,000 | 46,300,000 | 72,400,000 | |||
Debt Instrument, Unamortized Discount | 5,100,000 | 5,100,000 | 6,700,000 | |||
Derivative Liability | 41,000,000 | 41,000,000 | $ 800,000 | |||
Derivative, Gain (Loss) on Derivative, Net | $ 22,300,000 | $ 3,900,000 | $ 20,000,000 | $ 8,400,000 |
Note 12 - Income Taxes (Details
Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Income Tax Expense (Benefit) | $ 310 | $ 138 | $ 269 | $ 253 |
Note 13 - Net Loss Per Share 61
Note 13 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Net income (loss) | $ 620 | $ (13,566) | $ (36,751) | $ (28,874) |
Less deemed dividend (capital distribution to related parties) | (8,648) | (8,648) | ||
Less deemed dividend related to beneficial conversion feature on Series A preferred stock | (562) | (562) | ||
Less cumulative dividends on Series A and Series B preferred stock | (1,675) | (1,675) | ||
Net loss attributable to Amyris, Inc. common stockholders, basic | (10,265) | (13,566) | (47,636) | (28,874) |
Interest on convertible debt | 1,591 | 3,501 | ||
Accretion of debt discount | 1,846 | 3,479 | ||
Loss (gain) from change in fair value of derivative instruments | $ (19,116) | $ (37,803) | ||
Basic (in dollars per share) | $ (0.44) | $ (0.91) | $ (2.24) | $ (2) |
Net loss attributable to Amyris, Inc. common stockholders, diluted | $ (10,265) | $ (29,245) | $ (47,636) | $ (59,697) |
Basic (in shares) | 23,155,874 | 14,874,135 | 21,226,013 | 14,426,247 |
Effect of dilutive convertible promissory notes (in shares) | 2,652,275 | 2,827,714 | ||
Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted (in shares) | 23,155,874 | 17,526,410 | 21,226,013 | 17,253,961 |
Diluted (in dollars per share) | $ (0.44) | $ (1.67) | $ (2.24) | $ (3.46) |
Note 13 - Net Loss Per Share 62
Note 13 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | ||
Antidilutive securities (in shares) | 24,806,045 | 6,152,377 | 24,806,045 | 6,152,377 | |
Stock Options to Purchase Common Stock [Member] | |||||
Antidilutive securities (in shares) | 997,275 | 948,603 | 997,275 | 948,603 | |
Convertible Promissory Notes [Member] | |||||
Antidilutive securities (in shares) | [1] | 6,270,734 | 4,489,743 | 6,270,734 | 4,489,743 |
Common Stock Subject to Repurchase [Member] | |||||
Antidilutive securities (in shares) | 16,871,700 | 193,429 | 16,871,700 | 193,429 | |
Restricted Stock Units (RSUs) [Member] | |||||
Antidilutive securities (in shares) | 666,336 | 520,602 | 666,336 | 520,602 | |
[1] | The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 14 - Subsequent Events (De
Note 14 - Subsequent Events (Details Textual) - USD ($) | Aug. 07, 2017 | Aug. 03, 2017 | Aug. 02, 2017 | Jun. 30, 2017 | Jun. 30, 2016 | May 11, 2017 | Dec. 31, 2016 |
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | |||||
Proceeds from Issuance of Convertible Preferred Stock | $ 50,661,000 | ||||||
Subsequent Event [Member] | August 2017 Vito Warrants [Member] | |||||||
Class of Warrant or Right, Term | 5 years | ||||||
Subsequent Event [Member] | August 2017 Vito Dilution Warrants [Member] | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.0001 | ||||||
Preferred Stock Effective Conversion Price | $ 4.26 | ||||||
DSM International B.V. [Member] | |||||||
Reserved Second Tranche Securities | $ 25,000,000 | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 3,968,116 | ||||||
Ownership Percentage, To Have Right To Designate One DSM Director | 10.00% | ||||||
Ownership Percentage, Designated Director Threshold | 4.50% | ||||||
Second Tranche Closing, Anniversary Payment | $ 5,000,000 | ||||||
DSM International B.V. [Member] | Subsequent Event [Member] | DSM Warrants [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 3,968,116 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.30 | ||||||
Class of Warrant or Right, Term | 5 years | ||||||
DSM International B.V. [Member] | Subsequent Event [Member] | DSM Dilution Warrant [Member] | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.0001 | ||||||
Preferred Stock Effective Conversion Price | 6.30 | ||||||
Common Stock, Dividends, Per Share, Declared | $ 0.10 | ||||||
Vivo Capital LLC [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | |||||||
Shares Issued, Price Per Share | $ 4.26 | ||||||
Stock Issued During Period, Shares, New Issues | 2,826,711 | 2,826,711 | |||||
Proceeds from Issuance or Sale of Equity | $ 24,800,000 | ||||||
Vivo Capital LLC [Member] | Subsequent Event [Member] | August 2017 Vito Warrants [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,575,118 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.39 | ||||||
Vito Stockholder Agreement [Member] | Subsequent Event [Member] | |||||||
Ownership Percentage, Designated Director Threshold | 4.50% | ||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | ||||||
Maximum Number of Shares Registered, Percentage | 25.00% | ||||||
Series B Convertible Preferred Stock [Member] | DSM International B.V. [Member] | Subsequent Event [Member] | |||||||
Stock Issued During Period, Shares, New Issues | 25,000 | ||||||
Proceeds from Issuance of Convertible Preferred Stock | $ 24,800,000 | ||||||
Series D Convertible Preferred Stock [Member] | Vivo Capital LLC [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | |||||||
Stock Issued During Period, Shares, New Issues | 12,958 | 12,958 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | ||||||
Series D Preferred Stock [Member] | Subsequent Event [Member] | |||||||
Beneficiary Ownership, Conversion Percentage, Minimum | 9.99% | ||||||
Preferred Stock, Stated Value | $ 1,000 | ||||||
Preferred Stock, Conversion Price Per Share to Common Stock | 4.26 | ||||||
Common Stock, Dividends, Per Share, Declared | $ 0.0001 |